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CHAPTER I 
 
INTRODUCTION 
 
1.1 Background and Significance 
 
1.1.1 Endothelial Progenitor Cell Subsets in Vascular Disease 
Angiogenesis characterizes of a number of blinding ocular conditions, including 
diabetic retinopathy, macular degeneration, retinopathy of prematurity, and vein 
occlusion retinopathy to name a few. In angiogenesis, new blood vessels originate from 
existing venules by a series of events involving extracellular matrix remodeling, 
endothelial cell proliferation and migration and the formation and closure of the nascent 
vascular tubes(1). Recent studies have found that a large portion of this may be 
vasculogenesis as the result of bone marrow-derived stem cells incorporating into the 
neovascular tissue regions from the peripheral blood circulation.  
Adult bone marrow is known to contain a population of hematopoietic stem cells 
which are released into the blood stream where they home to sites of angiogenesis and 
become vascular endothelial cells. These endothelial progenitor cells (EPCs) were first 
isolated and characterized by Asahara et al.(2) and have been shown to be recruited to 
participate in a variety of vascular diseases. These cells can contribute to as much as 50% 
of the newly formed vessels in choroidal neovascularization (CNV)(3, 4) and have also 
been shown to participate in myocardial ischemia(5) and infarction(6), tumor 
infiltration(7), atherosclerosis(8, 9) and revascularization after a stroke(10, 11). 
Additionally, the impaired ability of these cells under certain diseases has been shown to 
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contribute to retinal degeneration(12, 13) and vascular disease in diabetes(14-17).  
However, a better understanding of how these cells function in vascular diseases is 
required in order to eventually develop a therapy that can be used to influence or control 
them. This understanding will most likely come in the form of studying the proteins that 
make up their surface. 
One such protein that is common to many hematopoietic and mesenchymal 
progenitor cells is endoglin. Endoglin (CD105) is a potential non-VEGF pathway protein 
that could be targeted in the treatment of neovascularization resulting from EPC 
incorporation. It is a transmembrane glycoprotein that is an accessory to the transforming 
growth factor β (TGFβ) receptor system(18).  Endoglin is also expressed on proliferating 
endothelial cells (ECs) and tumor types characterized by hypoxia(19-24). On endothelial 
and tumor cells, it is thought to be involved in differentiation, migration and 
proliferation(20, 25). Monoclonal antibody therapies have been shown to have some 
antiproliferative effects in cancer studies(26, 27). Furthermore, subsets of endothelial 
progenitor cells (EPCs) have been found to highly express CD105(28-30). Additionally, 
as marker of mesenchymal stem cells, endoglin has been shown on progenitor cells that 
increase vascular remodeling in models of myocardial infarction and rheumatic 
diseases(31, 32).Many investigators suggest that EPCs play a significant role in ocular 
neovascularization and that these cells could be targeted to influence that 
neovascularization(33, 34). Perhaps targeting EPCs through CD105 could prevent their 
differentiation and proliferation in the neovascular lesions seen in the angiogenic 
pathology of the eye. But this isn‟t the only potential therapeutic strategy targeting EPCs. 
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Several studies have demonstrated the efficacy of blocking the “homing” of EPCs 
in reducing vascular disease pathology. Grant et al.(4) show that by using and SDF-1 
antibody to inhibit the EPCs in a choroidal neovascularization model, the mean CNV 
vascular lesion is decreased by approximately 60%. Other studies have shown that the 
inhibition of L-Selectin and β2-integrins binding have been able to decrease EPC 
neovascularization in models of hind limb ischemia(35, 36). There are also suggestions to 
use these cells as therapeutic delivery devices of drugs and proteins to specific sites and 
in seeding grafts(37, 38).  
A common feature of most therapeutic interventions directed toward the 
inhibition of EPC function in disease has not differentiated among EPC subpopulations.  
Much work has elucidated a family of EPC subpopulations with varying cell surface 
expression profiles, which may have similar or distinct functions from each other in 
disease processes.  EPCs that are CD14+ positive, a monocyte surface marker, have been 
shown to incorporate into developing vessels and become endothelial cells(39, 40). In a 
similar way, EPCs expressing lymphatic lineage markers have also been shown to target 
neovascular tissue and become mature endothelial cells(41). EPCs that are CD34+ 
/CD133+ have been found to be more prolific in cell culture and when targeted to 
ischemic regions in vivo(2), while CD34- /CD133+ seem to be more adherent to SDF-1 
coated plastic dishes and SDF-1 expressing ischemic tissues(42). A diagram depicting 
several of these cell populations interacting with their respective tissue types is shown in 
Figure 1.1. VEGF is thought to be the principle mediator involved in retinal 
angiogenesis(43) and EPC subpopulations with VEGF receptors have been shown to have 
high proliferative capacities(40, 41). However, how do VEGFR expressing 
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subpopulations compare to others in adherence to angiogenic regions and proliferation? 
How do VEGFR2 expressing subpopulations differ in their effect on NV from VEGFR3 
subpopulations? Are the hematopoietic lineage progenitors (CD34+)(2), which were first 
discovered to be involved in NV more involved in the EPC tissue targeting observed or 
are CD14+ cells, one of the most recent subpopulations to be shown to take part in 
vascular disease pathology(39, 40)? In this study, we will identify methods to elucidate 
the interactions of these progenitors between subtypes. We will also develop methods to 
distinguish the interactions between specific subtypes, preexisting mature endothelial 
cells, and the effect of each subtype on vascular disease in the retina. 
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Figure 1.1. Diagram illustrating EPC subsets homing to specific vascular sites based on 
cell surface antigens. The EPCs originate in the bone marrow, mobilize into the systemic 
circulation and then extravasate into tissues determined by their individual cell surface 
antigens. Adapted from(44) - Nature Med.  9, 702 - 712 (2003). 
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1.1.2 Pre-Existing In Vitro and In Vivo Tools for the Study of Cell Trafficking 
Although initial studies have demonstrated the existence of EPC subpopulations, 
efforts to extensively determine the significance of antigenic variation on EPC function in 
neovascularization are limited.  Many tools are available for use exclusively within an in 
vitro environment.  These include blotting techniques, which detect proteins, RNA, or 
DNA presence within a biological sample, and flow cytometry, a quantitative technique 
utilized to probe molecular expression, cell cycle phase and viability of cells.  
Immunohistochemistry can be utilized to visualize a protein of interest in tissue sections.  
For many of these observations, in vivo corroboration has not been obtained, primarily 
since the assays cannot always reflect the disease scenario in which multiple cell types 
and biomolecules work in concert in its progression. 
No current techniques have been applied to study the complex interaction of 
multiple molecular and cellular participants in critical disease processes in vivo, such as 
angiogenesis, the focus of this study.  Tools for such multiplexed studies have yet to be 
developed.  Given the above limitations with in vitro assays, several attempts to probe in 
vivo activities on the single cell type or single biomolecules level have been reported(2, 
36, 42), many within the disease context of inflammation.  Radiolabeled monoclonal 
antibodies to the inflammatory cell adhesion molecules ICAM-1 and VCAM-1 were 
administered in vivo(45, 46).  The method, while a useful step in the effort to develop 
multiplexed in vivo studies, was limited by low signal to noise ratios, as well as the need 
for multiple compensatory calculations and estimations to separate the signal of one 
antigen from the other.  This stemmed from a lack of labeling methods that allowed for 
easily and accurately differentiating multiple proteins or samples of interest. Furthermore, 
7 
 
the method did not permit true real-time analysis.  A technique with the spatial and 
temporal resolution to capture leukocyte motility through the circulation was established 
by Nishiwaki and colleagues(47) using the fluorescent DNA-intercalating dye acridine 
orange (AO) in conjunction with scanning laser ophthalmoscopy (SLO)(48).  However, 
the method relies on the nonspecific staining of all nuclear material by the dye, thus 
making it impossible to distinguish multiple cell types.  A third method has been used to 
characterize VCAM-1 expression in vivo using multimodal fluorescent Cy5.5-conjugated 
antibody and peptide conjugates by the Weissleder laboratory(49, 50).  While this method 
is a significant achievement in the development of in vivo molecular profiling techniques, 
its utility in multispecies real-time imaging applications is markedly limited, since a 
specific laser and organic dye is required for each biomarker, raising issues of spectral 
overlap, photobleaching, and low signal to noise ratios.  Furthermore, this application 
only yielded single time-point data and failed to capture real-time dynamics of molecular 
expression.   
Efforts to image EPC trafficking in vivo have only recently been initiated.  Jin et 
al.(51) used a nonspecific cell labeling dye, CMTMR, to label cells ex vivo prior to 
reinfusion into a tumor-bearing mouse, but no provisions for multispectral imaging in the 
tumor circulation.  Furthermore, this study was concerned with the isolation of only 
CD34+ EPCs, which constitutes a very large population of EPCs and encompasses a 
number of cell types.  However, the real-time video microscopy and spatial resolution 
was sufficient for capturing single cells in the circulation.  Thus, if the method of Jin et 
al. was modified to accommodate multispecies imaging, as detailed studies of multiple 
cell types (e.g. genetically modified, therapeutically inhibited, etc.) would be facilitated.   
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1.2 Specific Aims 
 The field of research into endothelial progenitor cells is complex and difficult to 
interpret.  There are a number different investigators working on their individual 
subpopulation that they isolated in a unique manner with a unique or semi-unique set of 
cell surface antigens. Each population is, additionally, assayed in a specialized way 
corresponding to a certain tissue or disease process. All of these variables make it 
difficult to determine what cell populations might be important in a particular tissue or 
disease state, and complicated or impossible to compare. We hypothesized that a number 
of separate subpopulations of endothelial progenitor cells exist, but that only a single 
subpopulation or small subset of these populations is significantly involved in ocular 
neovascularization. These studies sought to develop methods for: (1) analyzing definitive 
EPC populations and (2) comparing them to one another in the context of ocular 
neovascularization. 
 
1.2.1 Specific Aim 1: Develop quantum dot coded EPC subpopulations and assess their 
recruitment to neovascular tufts 
 The development of quantum dot labeled EPCs is an invaluable tool used to both 
track EPCs in animals, but also to further develop sophisticated methods of analyzing 
EPCs functions in vitro.  
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1.2.2 Specific Aim 2: Develop high throughput, in vitro methods to analyze the 
angiogenic capacity of EPCs using quantum dot coded subpopulations 
 The development of in vitro analysis of EPC angiogenic capacity allows EPC 
subpopulations to be directly compared to one another, and aids in separating the 
individual aspects of EPC functions: homing to angiogenic sites, incorporating into and 
forming capillary tubes, and proliferating into neovascular lesions. 
 
1.2.3 Specific Aim 3: Using methods to analyze the angiogenic capacity of EPCs, 
determine the role of endoglin in oxygen-induced retinopathy 
 Using the methods developed in the previous two aims to determine the biological 
role of an EPC associated protein demonstrates the utility of this system of analysis. With 
this outline as an example, multiple EPC subpopulations can be compared, and their 
surface antigens and angiogenic signaling can be effectively examined in the context of 
ocular angiogenesis. 
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CHAPTER II 
 
MONITORING ENDOTHELIAL PROGENITOR CELL SUBPOPULATIONS IN 
ANGIOGENESIS USING QUANTUM DOT NANOCRYSTALS 
 
2.1 Introduction 
 
A number of blinding ocular conditions are characterized by angiogenesis, 
including diabetic retinopathy, macular degeneration, and retinopathy of prematurity.  A 
number of factors including proteins, lipids and cellular interactions contribute to the 
pathology seen in these disorders(52, 53). In 1997, Asahara and coworkers identified and 
characterized a circulating population of cells originating from the bone marrow 
designated endothelial progenitor cells (EPCs) that have been shown to be recruited to 
neovascular lesions and contribute to the vascular components of a variety of diseases 
including diabetic retinopathy and age-related macular degeneration(2-4, 54). In these 
diseases, EPCs roll along and adhere to the endothelial cells of the inner vascular wall of 
neovascular tissue to augment pathologic angiogenesis(11, 55, 56). Several animal 
models, which simulate these ocular diseases have been utilized to image EPCs for 
elucidation of these and other functions(4, 54).
 
 However, the specific factors governing 
EPC homing to tissue and the spectrum of their functions remain incompletely 
understood.  The emerging importance of EPCs in these diseases has motivated the 
development of methods to image EPCs in tissues with high sensitivity and specificity.    
Over the last decade, research has identified a class of bone marrow-derived 
circulating stem cells; endothelial progenitor cells (EPCs) that are capable of homing to 
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vascular lesions in the eye and contributing to pathological ocular neovascularization 
(NV).  In preclinical and biological studies, EPCs are frequently identified and tracked 
using a intracellularly-loaded fluorescent tracer, 1,1'-dioctadecyl-3,3,3',3'- 
tetramethylindocarbo-cyanine perchlorate-labeled acetylated LDL (DiI-acLDL).  
However, this method is limited by photobleaching and insufficient quantum efficiency 
for long-term imaging applications.  We have developed a method for conjugation of 
high quantum efficiency, photostable, and multispectral quantum dot nanocrystals (QD) 
to acLDL for long-term tracking of EPCs with improved signal to noise ratios.  
Specifically, we conjugated QD to acLDL (QD-acLDL) and used this conjugated 
fluorophore to label a specific CD34+ subpopulation of EPCs isolated from rat bone 
marrow with the same specificity as DiI-acLDL.  We then utilized this method to track 
CD34+ EPCs in a rat model of laser-induced choroidal neovascularization (L-CNV) to 
evaluate its potential for tracking EPCs in ocular angiogenesis, a critical pathologic 
feature of several blinding ocular diseases. 
  A majority of EPC populations cited in the literature originate from the bone 
marrow and are defined as being CD34 positive (CD34
+
), and incorporate acetylated low-
density lipoprotein (acLDL)(44, 55, 57-61).  Due to the latter characteristic, dye-labeled 
acLDL incorporation is often used to label and track these cells using the DiI-acLDL 
fluorophore conjugate (DiI = 1,1'-dioctadecyl-3,3,3',3'- tetramethylindocarbo-cyanine 
perchlorate).  However, this dye-based strategy is limited by low intensity and 
photostability, which complicates longitudinal studies of EPCs in disease models.  In this 
chapter, we describe an EPC imaging strategy that incorporates quantum dot nanocrystals 
(QD) as the fluorophore rather than DiI.  QD are superior to organic dyes in 
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photostability and fluorescence intensity, and thus enable more specific and prolonged 
visualization of EPCs in tissue.  Using QD, EPCs are isolated from bone marrow and 
labeled ex vivo.  The cells are then injected and imaged in a disease context using a rat 
model of laser-induced choroidal neovascularization (LCNV).   This animal model is 
used to model pathologic angiogenesis in neovascular age-related macular degeneration.  
 
2.2 Materials 
 
1. Six, four- to six-week-old Brown Norway rats (around 100 grams each) 
2. Isoflurane (Terrell) 
3. Hank‟s Buffered Salt Solution (HBSS): (1X solution): 5 mM KCl, 0.44 mM 
KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4, 3.3 mM NaHCO3, 5.5 mM D-
Glucose, pH 7.1-7.4 [easily contaminated by bacteria if not kept in a sterile 
location] 
4. AccutaseTM (A6964, Sigma) 
5. Swinging-bucket centrifuge 
6. Sterile 40 nm nylon mesh (Sefar America Inc., Fisher Scientific) 
7. EasySep® cell isolation system (18558, StemCell Technologies), including: 
EasySep® FITC Selection Cocktail (18152), magnetic nanoparticles (18150), and 
EasySep® magnet (18000) 
8. Hemacytometer (BD Biosciences, Bedford, MA) 
9. Five milliliter Falcon tube: (isolation tube): (352058, Becton Dickinson) 
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10. Phosphate-buffered Saline (PBS): (1X solution): 3.2 mM Na2HPO4, 0.5 mM 
KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4 
11. Isolation buffer: (1X solution): PBS, 2% fetal bovine serum (FBS), 1.0 mM EDTA 
[make fresh, important to keep this Ca
++
 and Mg
++
 free] 
12. FcR blocking antibody (112-001-008, Jackson ImmunoResearch Laboratories Inc.) 
13. Rabbit anti-CD34 FITC conjugated antibody (252268, Abbiotec) 
14. EGM-2 medium (CC-3162, Clonetics): contains FBS, hydrocortisone, epidermal 
growth factor, and antibiotic [keeps for a few weeks at 4˚C] 
15. 100X antibiotic/antimycotic solution (A5955, Sigma) [keep at -20 until needed] 
16. Human Low-density lipoprotein (Biomedical Technologies Inc.) 
17. Sulfo-NHS-biotin (Pierce protein research products, Thermo Fischer Scientific) 
18. Borate buffered saline (BBS): (1X solution): 10 mM sodium borate, 150 mM 
NaCl, pH 8.2 
19. G-25 Sephadex columns (GE Lifesciences) 
20. Sulfo-NHS-acetate (Pierce protein research products, Thermo Fischer Scientific) 
21. Sephacryl 400HR (GE Lifesciences) 
22. QD655: Quantum dots emitting 655 nm light (Invitrogen) 
23. DiI-acLDL (BT-902, Biomedical Technologies Inc.) 
24. 4',6-diamidino-2-phenylindole (DAPI) (Sigma, D9532) 
25. Chamber SlidesTM (177429, Lab-Tek) 
26. Light microscope similar to the AX70 (Olympus) 
27. 100 Watt mercury lamp and filter cubes (Olympus) 
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28.  Provis system digital camera DP71 (Olympus), computer (Dell) and DP controller 
software (Olympus) 
29. Eight, 100 gram, Brown Norway rats 
30. General anesthetic: 80/12 mg/kg ketamine/xylazine (K113, Sigma) 
31. Local anesthetic: 0.5% proparacaine drops 
32. Dilating eye drops: 2.5% phenylephrine and 1% atropine 
33. 2.5% Gonak solution (Akorn) used with glass coverslips to help visualize the 
fundus of the retina and keep the eye moist during the procedure. 
34. Slit lamp (Carl Zeiss Meditec) with a laser delivery system 
35. Argon Green Laser (Coherent, Polo Alto; CA, USA) 
36. 50μl Hamilton syringe (Hamilton Co.) and a 30-gauge 19˚ beveled needle 
(Hamilton Co.) 
37. Isopropyl alcohol swabs 
38. Dissection equipment: scalpel, jewelers forceps, Castroviejo scissors (Miltex, Inc., 
York, PA) 
39. 37% formaldehyde solution (Sigma) 
40. Bovine serum albumin (BSA) (Sigma) 
41. FITC conjugated isolectin B4 (L2895, Sigma) 
42. Triton X-100 (Sigma) 
43. Clear glass slides and Gel/Mount slide coverslipping medium with anti-fading 
reagents (#M01, Biomedia) 
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2.3 Methods 
 
The methods below outline: (1) immunomagnetic isolation of EPCs from bone 
marrow, (2) intracellular loading of EPCs with QD, (3) monitoring of QD loading 
efficiency, and (4) imaging of QD-loaded EPCs in a rat model of LCNV.  While these 
methods were specifically used for imaging EPCs in LCNV, the techniques herein could 
be applied toward the labeling and imaging of EPCs in other vascular diseases including 
cancer and diabetes, by selection of a relevant animal model.   
 
2.3.1 Immunomagnetic isolation of endothelial progenitor cells from bone marrow  
Cells were isolated from six, four- to six-week-old Brown Norway rats. The 
animals were sedated with isoflurane (Terrell) vapors, and then euthanized by 
decapitation. Their tibias and femurs were removed, and the bone marrow was isolated 
from these bones in Hank‟s Buffered Salt Solution (HBSS) [5 mM KCl, 0.44 mM 
KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4, 3.3 mM NaHCO3, 5.5 mM D-Glucose, pH 
7.1-7.4]. The marrow tissue was then triturated and digested in Accutase
TM
 (A6964, 
Sigma) for five minutes. Following the digestion, the remaining cells were washed three 
times in HBSS followed by centrifugation to remove extracellular matrix debris, and 
filtered through a double layer of sterile 40 nm nylon mesh (Sefar America Inc., Fisher 
Scientific, Hanover Park, IL). Following this step, the remainder of this procedure was 
carried out under a laminar flow hood using aseptic technique. 
The cell mixture was then purified in order to enrich for CD34
+
 cells using an 
immunomagnetic purification method similar to that used by Su X. et al. for the isolation 
of CD31
+
 endothelial cells(62). We used the EasySep® cell isolation system (18558, 
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StemCell Technologies). Initially, cells were counted using a hemacytometer to ensure 
that no more than 2 X 10
8
 cells per milliliter were in an isolation tube (352058, Becton 
Dickinson).  These cells were then centrifuged and resuspended in 1.0 mL of an isolation 
buffer [3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4, 2% 
fetal bovine serum (FBS), 1.0 mM EDTA].  An FcR blocking antibody (112-001-008, 
Jackson ImmunoResearch Laboratories Inc.) was then added at 50 µl/ml.  Next, 3.0µg/ml 
of a rabbit anti-CD34 FITC conjugated antibody (252268, Abbiotec) was added and the 
mixture was allowed to incubate for 15 minutes at room temperature. Following this 
incubation, the EasySep® FITC Selection Cocktail (18152, StemCell Technologies) was 
added at 100 µl/ml cells and allowed to incubate for another 15 minutes at room 
temperature. Finally, the magnetic nanoparticles (18150, StemCell Technologies) were 
mixed in at 50 µl/ml cells and allowed to incubate for 10 minutes. The cell suspension 
was then brought to a total volume of 2.5 mL with isolation buffer and gently mixed in 
the tube to ensure a homogenous suspension. The cells were then placed into the 
EasySep® magnet (18000, StemCell Technologies) and allowed to sit for five minutes, 
before the tube and magnet were carefully picked up and inverted into a waste container. 
This resuspension/magnetic pelleting/inversion process was repeated twice.  After the 
third inversion, the cells were resuspended in EGM-2 media (CC-3162, Clonetics) 
containing 10% fetal bovine serum, 1 μg/ml hydrocortisone, 10 ng/ml epidermal growth 
factor and 5 ml/500 ml of 100X antibiotic/antimycotic solution (A5955, Sigma) and 
plated onto 60 mm plastic dishes to be expanded for one full passage before further use.   
Prior to in vitro imaging of QD in EPCs, EPCs were seeded at 5000 cells per well 
on 4-well Chamber Slides
TM
 (177429, Lab-Tek) and incubated for 2-4 days at 37°C until 
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60% confluence was achieved.  For injection of QD-labeled EPCs in the LCNV model 
(3.4), EPCs were maintained in 60 mm cell culture dishes until detachment in Accutase 
and resuspension of EPCs to the desired density.   
 
2.3.2 Conjugation of acLDL to QD 
In order to produce fluorescently labeled acLDL, 100 µl of human low density 
lipoprotein (LDL) (5 mg/mL) was taken and added to 10 µl of a 20 mM solution of sulfo-
NHS-biotin in borate buffered saline (pH = 8.2). The mixture was allowed to react for 30 
minutes at room temperature. Following this reaction, the sample was purified for 
removal of excess reagent using G-25 Sephadex gravity column filtration with borate 
buffered saline as the elution buffer.  1.0 mg of sulfo-NHS acetate was added to the 
product diluted in 1.0 mL total borate buffered saline and the solution was incubated for 
one hour.  The conjugated protein was then purified using a G-25 column with borate 
buffered saline, as the elution buffer, to remove excess acetylation reagent, yielding a 
pure solution of biotinylated acLDL.  The conjugated protein was then incubated with 5.0 
ul of streptavidin-functionalized QD655 (QD emitting 655 nm light) for 30 minutes at 
37˚C.  This solution was characterized for conjugation efficiency by size exclusion 
chromatography on Sephacryl HR400 resin and was found to exhibit three acLDL 
molecules per QD.     
 
2.3.3 Intracellular loading of EPCs with acLDL-QD 
In order to label the EPCs with QD-acLDL and DiI-acLDL (BT-902, Biomedical 
Technologies Inc.), the cells were incubated with 2.0 µg/ml of each acLDL in growth 
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media for six hours at 37˚C. Fifteen minutes prior to ending the incubation, DAPI 
(Sigma, D9532), a nuclear counterstain, was added to the cells in an amount to bring the 
final concentration to 600 nM.  Following the six hour incubation, the media was 
removed, and the cells were washed thrice in pre-warmed (37˚C) PBS. After the wash, 
the cells were coverslipped to be visualized by fluorescence microscopy using 
Gel/Mount. 
 
2.3.4 Monitoring of QD loading efficiency 
The EPCs were imaged on Chamber Slides
TM
 (177429, Lab-Tek) labeled directly 
with QD-acLDL and DiI-acLDL using fluorescence microscopy.  These cells can be 
imaged on an upright or inverted fluorescent confocal or widefield microscope that has 
the appropriate filter set to distinguish the 568 nm fluorescence of the DiI, the 655 nm 
fluorescence of the QD, and the 454 nm fluorescence of the DAPI without significant 
spectral overlap. In this chapter, we used an AX70 microscope, (Olympus, Japan) 
containing filter cubes with 460/40 nm, 570/30 nm, and 655/20 nm emission filters. 
Images of the cells were captured using a digital camera attached to the Provis system 
(DP71, Olympus, Japan) coupled to a computer with image capture software (DP 
Controller, Olympus, Japan). However, this analysis can be completed with a comparable 
imaging system. 
 
Imaging of the acLDL labeled EPCs 
 
1. Position the coverglassed slides containing the labeled EPCs on the stage of the 
fluorescent microscope. 
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2. Using dim, transmitted light, bring the cells on the slide into focus. 
3. Using 518 nm of incident light, excite the cells labeled by DiI-acLDL and collect an 
image of resulting fluorescence emission of cells with the 570/30 nm band-pass 
filter. Capture this image first, since DiI is the most sensitive fluorophore to 
photobleaching. 
4. Without moving the slide, capture the next image of the DAPI-stained cell nuclei 
using a 360 nm incident light with the 460/40 nm band-pass filter. 
5. Finally, capture the QD-acLDL labeled cells using the 360 nm incident light (or if 
not available, an excitation wavelength of < 480 nm) with the 655/20 nm band-pass 
filter. Note that the smaller wavelength incident light will produce a stronger 
excitation of the QDs.  In addition, for optimal results, illuminate the QD-loaded 
cells for at least 2 minutes using these incident light settings to induce maximal QD 
fluorescence emission.   
 
The images shown in Figure 2.1 demonstrate that EPCs can be labeled with QD-acLDL 
with equal efficiency to DiI-acLDL labeling, however, the QD-acLDL labeling results in 
bright and photostable EPCs that can be tracked in culture for longer periods of time. 
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Figure 2.1. Imaging of CD34+ EPCs with fluorophore-acLDL conjugates. Panel A 
shows the internalized DiI-acLDL conjugate throughout the cytoplasm. Panel B shows 
the same field of cells as A, but with internalized, cytoplasmically-distributed QD655-
acLDL.  Panel C exhibits the DAPI-labeled nuclei of the cells in the same field of view.  
These panels demonstrate that DiI-acLDL and QD655-acLDL are targeted to and taken 
up by the same EPC populations.  Subsequent analysis by fluorescence microscopy 
indicated that cells labeled with DiI became dim within 6 minutes of continuous 
illumination, but that QD-labeled cells lost only 3-5% of initial fluorescence for every 10 
minutes of continuous illumination during a 60 minute analysis. 
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2.3.5 Analysis of QD-loaded EPCs in a rat model of ocular angiogenesis  
 
Generation of LCNV model 
In this study, CNV, a subretinal form of angiogenesis in which blood vessels 
abnormally grow beneath the retinal photoreceptors, is produced in eight, Brown Norway 
rats, each weighing 100 grams. This CNV was produced by administering krypton laser 
radiation between the major retinal vessels of the fundus as we and others have 
previously published(63-66). In this protocol, the animals were anesthetized with an IP 
injection of 80/12 mg/kg ketamine/xylazine (K113, Sigma), Proparacaine (0.5%) drops 
for corneal anesthesia and pupils dilated with phenylephrine (2.5%) and atropine sulfate 
(1%) drops. A handheld coverslip and (2.5%) Gonak solution (Akorn) was used as a 
contact lens for the maintenance of corneal clarity during photocoagulation. Animals 
were positioned before a slit lamp (Carl Zeiss Meditec, Inc; Jena, Germany) laser 
delivery system. An argon green laser (Coherent, Polo Alto; CA, USA) was used for 
photocoagulation (532 nm wavelength; 360 mW power; 0.07-s duration; and 50 μm spot 
size). The laser beam was focused on Bruch‟s membrane with the intention of rupturing 
it, as evidenced by subretinal bubble formation without intraretinal or choroidal 
hemorrhage at the lesion site. Each lesion was made between the major vessels of the 
retina for a total of six lesions per eye concentrically applied approximately two optic 
discs from the center. The choroidal capillaries proliferated through the break in Bruch‟s 
membrane into the disrupted outer layers of the retina. Laser rupture sites, which had 
subretinal bleeding at the time of lesion creation, were excluded from analysis and 
represented less than 10% of total rupture sites in each treatment group.  With minor 
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operator training, this procedure can be completed efficiently and reliably such that up to 
20 rats per day can be induced for LCNV as studies may require.   
 
Injection of QD-acLDL labeled EPCs into LCNV model 
 
Seven days after laser treatment, the animals received a tail vein injection of 1 × 
10
6
 EPCs labeled with QD655-acLDL in a volume of 40 μl (PBS vehicle) using a 50 μl 
syringe (Hamilton Co.; Reno, NV) and a 30-gauge needle with a 19˚ bevel. These cells 
had been labeled as previously described in subheading „Conjugation of acLDL to QD‟. 
For the injection, the rats were anesthetized by isoflurane (Terrell) inhalation, and the tail 
was wiped with an isopropyl alcohol swab. The injection was made in either of the lateral 
veils along the base of the animal‟s tail. As the needle was advanced for the injection, the 
plunger was pulled back slightly in order to see a flash of blood in the syringe, ensuring 
the needle was properly in the vein. Fourteen days following laser application, animals 
were sacrificed by cervical dislocation to measure the amount of CNV at the Bruch‟s 
membrane rupture sites.  
 
Characterization of EPCs in retinal neovascular tissue 
 
After the animals were sacrificed, eyes were immediately enucleated (removed 
from the orbit) and placed in fixative, and the cornea, iris, and lens were removed.  The 
retina was peeled away from the fundus gently using a hemostat to reveal the choroid-
sclera-RPE section.  This section was flattened on a slide, mounted in Gel/Mount, and 
coverslipped.  Endothelial cells and extracellular matrix components were stained to 
reveal the areas of neovascularization.  Areas of abnormal vascular growth were 
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measured via computer-assisted image analysis using high-resolution digital images of 
the stained sclera-choroid-RPE flat-mounts. The details of this process are described 
below: 
 
Dissection and analysis of neovascularization: 
1. Enucleate the eyes and place them into labeled containers with 10% neutral 
buffered fixative solution [90% v/v PBS and 10% v/v 37% formaldehyde solution] 
for 2 hours at 4°C.  
2. Dissect out the choroid, sclera and RPE. Make sure to remove the entire retina from 
the RPE surface and remove the cornea, lens and iris as well.  
3. Place each dissected sample into a labeled 24-well plate well for the staining. 
4. In the well, wash the samples with PBS for 5 minutes.  
5. Using 5% BSA in PBS, block the samples on a shaker for 1 hour at room 
temperature. 
6. Next wash each sample with PBS 3 times for 5 minutes each. 
7. Completely cover and submerge each dissected sample with a solution of PBS with 
4.0 μg/ml FITC conjugated isolectin B4 (L2895, Sigma) and 0.1% Triton X-100, 
and incubate for 24 hours at 4°C on shaker. 
8. Remove the staining solution and wash with PBS 3 times for 5 minutes each. 
9. Mount the choroidal flat-mounts on the slides attempting to make them as flat as 
possible on the glass. Several cuts from the periphery of the sclera toward the optic 
nerve should help with this. Use Gel/Mount (#M01, Biomedia) with anti-fading 
reagents to prevent the FITC from bleaching.  
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Fluorescence imaging of LCNV lesions: 
1. Position the coverglassed slides containing the choroid-sclera-RPE flat-mount on 
the stage of the fluorescent microscope. 
2. Using dim, transmitted light, bring a one lesion of the flat-mount on the slide into 
focus. This is best accomplished using a 20X or 40X objective. 
3. Using 488 nm of incident light, excite the cells labeled by FITC-Isolectin B4 and 
obscure the fluorescence with the 525/20 nm band-pass filter. Capture this image 
first, since FITC is the most sensitive fluorophore to photobleaching.  Isolectin B4 
labels all endothelial cells within blood vessels, including EPCs. 
4. Without moving the slide, capture an image of the QD-acLDL labeled cells using 
the 360 nm or 488 nm incident light with the 655/20 nm band-pass filter. Note, 
again, that the smaller wavelength incident light will produce a stronger excitation 
of the QDs.  These settings will reveal the presence of EPCs in the specimen which 
can be distinguished from other Isolectin B4 positive, mature endothelial cells. 
 
The results of our experiment shown in Figure 2.2 demonstrate that the QD-acLDL 
labeled EPCs make up a large portion (62% of the total lesion size) of the lesions, and 
that they frequently seem to coalesce in the middle of the lesion. This would suggest that 
they are homing to the developing lesions through the blood stream and adding to the 
growth of the lesions through their own proliferation and, possibly, through the release of 
growth factors encouraging mature endothelial cells to proliferate. This method of cell 
labeling and tracking could be used to efficiently track and study the effects of these 
EPCs or multiple subtypes of EPCs influencing these neovascular lesions.  
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Figure 2.2. Imaging of CD34+ EPCs labeled with QD655-acLDL in the lesions of 
LCNV rats undergoing angiogenesis.  Panels A and B show two different CNV lesions 
labeled with Isolectin B4-FITC conjugate (all endothelial cells).  Panels C and D show 
the QD655-acLDL labeled CD34+ EPCs from A and B, respectively, that were injected 
into the tail vein of LCNV model rats seven days prior to ex vivo analysis.  QD-labeled 
EPCs homed to the neovascular lesions in the choroid in large masses or alternatively, 
arrived in small numbers and proliferated to comprise up to 62% of neovascular lesion 
area.  This is a clear demonstration that QD-acLDL labeled EPCs can be reinjected into 
animals, and tracked for longer periods of time relative to conventional methods, for 
detailed analysis of EPC function in ocular angiogenesis. 
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CHAPTER III 
 
IN VITRO PARALLEL PLATE FLOW CHAMBER ASSESSMENT OF 
ENDOTHELIAL PROGENITOR CELL HOMING 
 
3.1 Introduction 
 
Bone marrow-derived endothelial progenitor cells (EPCs) have been shown to 
play a significant role in the neovascularization of vascular diseases. In many of these 
diseases, including diabetic retinopathy and age-related macular degeneration, elevated 
stromal derived factor-1 (SDF-1) is observed in the neovascular tissue, and this is 
believed to play an important role in EPC homing function.  Little is known about other 
factors that might contribute. This study sought to develop an in vitro system of 
evaluating EPC homing capacity in conditions relevant to ocular disease states. Bone 
marrow was isolated from 4-6 week old Brown Norway rats and a population of EPCs 
was identified using the markers CD34, CD133 and CXCR4 in fluorescence-activated 
cell sorting experiments. EPCs were labeled with quantum dot conjugated acetylated 
LDL. Labeled EPCs and mature endothelial cells (ECs) were placed into a parallel plate 
flow chamber (PPFC) [Glycotech Corporation] in separate experiments. In the first, cells 
were allowed to flow at 15 dynes/cm
2
 shear stress over exposed extracellular matrix 
(ECM) and in the second, over conditioned endothelial monolayer (EML). The ECM 
conditions tested were hyaluronic acid (HA) or chondroitin sulfate (CS) with and without 
SDF-1. EMLs were conditioned by a 24-hour pretreatment in either hypoxia (0% oxygen) 
or normoxia (20.9% oxygen). In the ECM studies, EPCs were found to be 3-fold 
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(p<0.001) more adherent to HA than CS, and this adherence was increased 67% (p<0.01) 
with the addition of SDF-1 to HA. EPC adherence to HA + SDF-1 was reduced by 56% 
(p<0.01) by incubating the EPCs with anti-CXCR4 for 10 minutes prior to their addition 
to the PPFC. Compared to the ECs, EPCs were 59% (p<0.01) more adherent to HA 
alone, and 2.6-fold (p<0.001) more adherent to HA + SDF-1. In the EML studies, EPC 
adherence was increased by 33% (p<0.05) when EML were treated with hypoxia relative 
to normoxia. The in vitro system has demonstrated adherence of EPCs and ECs to 
surfaces chosen to model damaged blood vessel walls found in ocular neovascular 
diseases. This high throughput system can now be used to further characterize homing in 
more specific EPC subpopulations and to define the roles of EPCs in pathological 
disorders of the eye. 
A number of blinding ocular conditions are characterized by angiogenesis, 
including diabetic retinopathy, macular degeneration, retinopathy of prematurity, and 
vein occlusion retinopathy to name a few. The ocular angiogenesis and 
neovascularization of diabetic retinopathy (DR) and age-related macular degeneration 
(AMD) cause the greatest blindness in working-aged Americans and individuals 65 years 
or older in developed countries (67, 68). A number of factors including proteins, lipids 
and cellular interactions contribute to the pathology seen in these disorders. In 1997, 
Asahara and coworkers discovered a circulating population of cells originating from the 
bone marrow termed endothelial progenitor cells (EPCs) that have been shown to be 
recruited to neovascular lesions and to contribute to the vascular components of a variety 
of diseases including DR and AMD (2-4, 54).  
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EPCs have been characterized by a number of cell surface antigens and 
distinguishing activities. A strong component of the “homing” ability of these cells has 
been linked to a chemokine receptor (CXCR4) on the surface of EPCs. The ligand for 
CXCR4, SDF-1 (stromal-derived factor-1), is increased in neovascular lesions and 
thought to attract EPCs to developing neovascular areas (57). These cells have also been 
isolated by the surface antigens CD133 and CD34, which are glycoproteins found 
specifically on stem and progenitor cells (57-59). EPCs have also been found to roll along 
and adhere to the endothelial cells of the inner vascular wall of neovascular tissue (55, 
56). Relatively little is understood about the interactions of these characteristic surface 
antigens and there potential rolls in the recruitment of EPCs to specific vascular lesions 
and tissues. This study sought to develop an in vitro system of evaluating EPC homing 
capacity in conditions relevant to ocular disease states, but which may also have utility in 
modeling other tissue types and disease states. 
 
3.2 Experimental Procedures 
 
3.2.1 Cell Isolation and Preparation 
 Cells were isolated from six, four- to six-week-old Brown Norway rats. The 
animals were sedated with methoxyflurane vapors, and then euthanized by decapitation. 
Their tibias and femurs were removed, and the bone marrow was isolated from these 
bones. The marrow tissue was then triturated and then the remaining cells were washed 
once with erythrocyte-lysing solution (154mM NH4Cl, KHCO3 10mM, EDTA 82M) by 
centrifugation. The cells were then washed three times by centrifugation with phosphate 
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buffered saline to remove extracellular matrix debris. The cells were then further isolated 
according to cell surface antigens by FACS as described in section 3.2.2. This cell 
mixture was then plated onto plastic dishes and grown in EGM-2 media (Clonetics) 
containing 10% fetal bovine serum, 1ug/ml hydrocortisone, 10ng/ml epidermal growth 
factor and 5ml/500ml of 100X antibiotic/antimycotic solution (Sigma) for one full 
passage before use in vitro or labeled directly and used in the FACS assay to ensure the 
cells maintained surface expression of CD34 and CD133. 
 In order to label these cells with QD-acLDL or Qtracker (Invitrogen), the cells 
were incubated with 2ug/ml of QD-acLDL or 1ug/ml of Qtracker (as directed) for four to 
six hours, then removed from the dish using Accutase
TM
 (Sigma) followed by 
centrifugation and resuspension to the desired concentration in PBS before use in the in 
vitro assays. 
 
3.2.2 Fluorescence Activated Cell Sorting (FACS) 
For all of the surface antigens investigated, isolated bone marrow was taken from 
the rats as described above and incubated in a 200 g/ml of the appropriate blocking IgG 
for 10 minutes in an ice bath. A 1:500 dilution of the unconjugated primary antibody was 
then added to the solution. The antibodies used were anti-CXCR4 (Santa Cruz), anti-
CD133 (Abcam and Santa Cruz) and anti-CD34 (Abcam). Appropriate non-labeled 
controls were set aside at this time as well. This suspension was incubated on ice for 
another 15 minutes. The cells were centrifuged at 1500×g for 3 minutes at 4°C and then 
resuspended in a 1:2000 dilution of the secondary antibody (Jackson Labs) conjugated to 
quantum dots (em. 655 and 525) using an Invitrogen antibody conjugation kit. This 
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solution was also incubated 15 minutes in an ice bath. The cells were then centrifuged for 
3 minutes at 1500×g and 4°C. The cells were sorted on a 3-laser BD LSRII cell sorter 
(BD Biosciences) at the Vanderbilt Flow Cytometry Core. 
 
3.2.3 In Vitro Parallel Plate Flow Chamber (PPFC) Assay: 
 
PPFC and Extracellular Matrix (ECM)-Coated Adherence assay 
 Cells grown in culture and labeled with either QD-acLDL or Qtracker were using 
at 1-2 X 10
6 
cells/ml. The cells were placed into a parallel plate flow chamber (PPFC) 
(Glycotech Corporation). The chamber used has a flow width of 1.00cm and a height of 
0.010 in. Throughout these studies, a flow rate consistent with a shear stress of 15 
dynes/cm
2 
was used. Slides in these experiments were coated with 10g/ml hyaluronic 
acid (HA) or chondroitin sulfate (CS), a similar disaccharide polymer. These were diluted 
in PBS (buffered with 20mM bicarbonate at pH 8.5) in the presence of 2g/ml bovine 
serum albumin (BSA) carrier. Coated slides were allowed to sit at 37°C for two hours 
and then washed three times with PBS and blocked with (20g/ml) BSA for 2 hours at 
room temperature. For the slides also coated with SDF-1, 10g/ml SDF-1 diluted in PBS 
with 2g/ml bovine serum albumin (BSA) carrier was allowed to sit for 30 minutes at 
room temperature before being blocked. The slides were assembled as the lower wall of 
the PPFC and mounted on the stage of an inverted microscope. Cells that were pre-
treated to block the CXCR4 receptor were treated for 30 minutes with a 1:500 dilution of 
the antibody before being used in the assay. Images were captured of the flowing cells 
every 300ms for 5 to 15 minutes and cell counts and rolling velocities were determined at 
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frequent time points using Image Pro-Plus tracking software. A diagram of this PPFC is 
shown in Figure 3.1. 
Hypoxia and Scratch Endothelial Monolayer Injury Assays 
These studies functioned similarly to those in the adherence assay, with the 
substitution of the ECM-coated slides with slides having a confluent monolayer of 
endothelial cells cultured on their surface. These cells were either mature endothelial 
cells, cultured under normoxic conditions, or hypoxic conditions for 24 hours prior to 
their use in the PPFC. Monolayers of EPCs were also used. Additionally, monolayers of 
endothelial cells were cultured to confluence and then scraped down the middle of the 
culture removing a small line of ECs approximately 15 minutes before being used in the 
assay. This models a mechanical injury to the cells and exposes the ECM on which the 
cells were growing. Again, images were captured of the flowing cells every 300ms for 5 
to 15 minutes and cell counts and rolling velocities were determined at frequent time 
points using Image Pro-Plus tracking software. 
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Figure 3.1. Parallel plate flow chamber diagram. (A) This diagram depicts the bottom 
slide of the PPFC with two separate populations of cells [in red and green] flowing at 
varied speeds. To the right, this same slide is shown with its top cover slide and attached 
tubing. (B) This diagram depicts the bottom slide with a cell monolayer in green and a 
separate cell population in red flowing over the monolayer. 
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3.3 Results 
 
3.3.1 In Vitro Homing of EPCs to Specific Surfaces in a Parallel Plate Flow Chamber 
In these experiments, EPCs were used in a parallel plate flow chamber to 
determine the homing and adherent ability of the EPCs in vitro. The EPCs were propelled 
in a media solution at 37°C at a speed to ensure a shear stress on the observed plate 
surface of 15 dynes/cm
2
. In Figure 3.2, panels A and B show surface plots made from 
images like those in panels C-F. These surface plots aid in determining the number of 
cells adhering to a surface at any particular point in time. Here it can be observed that the 
surface CS (A) has much less adherence than SDF-1 (B). Panels C-F represent still 
images of the chamber‟s plate surface after 5 minutes of flow. It can be seen from the 
panels that SDF-1 (E) has the greatest cell adherence, which was reduced by anti-CXCR4 
treatment of the EPCs. Hyaluronic acid alone had a moderate amount of attachment of 
the EPCs and a similar disaccharide polymer, chondroitin sulfate, had very little 
adherence by the EPCs.  
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Figure 3.2. Analysis of EPCs adhesion to specifically coated surfaces. (A, B) Surface 
plots of cell adhesion to chondroitin sulfate and SDF-1, respectively. Photographs of 
cellular adhesion on (C) chondroitin sulfate (CS), (D) hyaluronic acid (HA), (E) HA+ 
SDF-1, (E) SDF-1 + anti-CXCR4 pre-treatment of EPCs. 
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Figures 3.3 and 3.4 go into more depth in this experiment showing twelve second 
time intervals of the attachment of the cells to each of the coated surfaces with SDF-1 and 
a control SDF-1 + anti-rat antibody pre-treatment demonstrating the greatest cell 
adherence followed by HA and a commercially available extracellular matrix, attachment 
factor (Invitrogen). Finally, SDF-1 + anti-CXCR4 pretreatment and CS demonstrated the 
least amount of adherence of EPCs under these conditions for the entire time course. 
Figure 3.4 specifically shows the relative accumulation of adherent cells over the course 
of the five minutes observed. 
Figures 3.5 and 3.6 depict a set of experiments where the adherence of EPCs is 
directly compared to that of mature vascular endothelial cells on HA, CS and SDF-1. 
Under these circumstances, mature ECs did increase their adherence to HA in 
comparison to CS, but were unaffected by the addition of SDF-1. On the contrary, EPCs 
attached much more readily to HA in comparison to their own CS adherence in addition 
to that of ECs to HA at all time points observed. Figure 3.6 specifically shows the 
relative accumulation of adherent cells over the course of the five minutes observed. Over 
the observed flow period, EPC adherence to SDF-1 was the greatest by nearly 2-fold 
above that to HA and nearly 3-fold better than the adherence of ECs to SDF-1. 
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Figure 3.3. The adherence of EPCs over a period of 5 minutes to a variety of proteins 
coated onto a glass surface. Cell count per mm
2
 at 12 second intervals for each coated 
surface.  
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Figure 3.4. Relative adherence of EPCs to varied surface coatings and treatment after 
five minutes of continuous flow at 15 dynes/cm
2
. 
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Figure 3.5. The adherence of EPCs to a variety of proteins coated onto a glass surface 
compared to the adherence of vascular endothelial cells (ECs) over a period of 5 minutes. 
The graph shows cell counts per mm
2
 at 12 second intervals for each coated surface.  
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Figure 3.6. The Relative adherence of EPCs and ECs to a variety of proteins coated onto 
a glass surface over a period of 5 minutes at a continuous flow of 15 dynes/cm
2
. * p<0.02 
using a Student‟s T-test relative to hyaluronic acid control. 
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3.3.2 Assessment of EPC Homing and Recruitment on Endothelial Monolayers 
In this set of experiments, EPCs are either propelled over a surface of endothelial 
cells in a monolayer culture or over an extracellular matrix (ECM)-coated surface. As the 
cells are flowing over the monolayer culture, they are assessed for recruitment to this 
monolayer by reduced rolling velocities. Figure 3.7 illustrates the staining of EPCs 
labeled with Qtracker (Invitrogen, 655nm emission Q-dots) adhering and rolling on an 
endothelial monolayer also labeled with a different wavelength quantum dot (525nm em. 
Q-dots). The monolayers tested were either cultured in normoxic conditions, in hypoxia 
(<1% oxygen for 24 hrs), a monolayer of EPCs or, as a control, a monolayer of mature 
EC cultured in normoxic conditions with mature endothelial cells flowing over them 
rather than EPCs. The experiments with ECM-coated surfaces were similar to those done 
in section 3.3.1 above with the rolling velocities measured rather than the cell adherence. 
Figure 3.8 depicts the slightly decreased velocities of endothelial cells on HA in 
comparison to CS. Just as in section 3.3.1, SDF-1 had no effect on the recruitment of 
mature ECs. However, EPCs showed a significant decrease in rolling velocity on a HA 
relative to EPCs on CS and ECs on HA, and a further decrease in velocity with the 
addition of SDF-1. 
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Figure 3.7. EPCs labeled in red (655nm em. Q-dots) adhering and rolling on an 
endothelial monolayer labeled in green (525nm em. Q-dots). This Q-dot system was used 
in conjunction with Image Pro-Plus software to more easily track the movement of the 
EPCs in a single plane of focus. 
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Figure 3.8. Analysis of adherence of EPCs and ECs to endothelial monolayers and 
specific adherence surfaces. Measurements of the rolling velocities of EPCs and ECs on 
HA, CS and SDF-1 for comparison to the homing adherence studies in section 3.3.1. * 
p<0.05 using a Student‟s T-test relative to hyaluronic acid control. 
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Figure 3.9 demonstrates the increased recruitment (decreased rolling velocity) of 
EPCs on hypoxia treated endothelial monolayers. This decrease is more than that of EPCs 
on normoxic EC monolayers, which show slower rolling velocities than either EPCs 
rolling over EPC monolayers or ECs rolling over EC monolayers. 
 
3.3.3 Assessment of EPC Homing and Recruitment in an Endothelial Injury Model 
In an attempt to further study the recruitment of EPCs to injured endothelium, 
EPCs were propelled over an endothelial monolayer scratch injury model. Figure 3.10 
illustrates the edge of the scratch where unaltered endothelial cells and injured cells can 
be seen in the same frame. The monolayer is shown in green (Qtracker; Invitrogen, 
525nm em. Q-dots) while the EPCs are stained red (Qtracker; Invitrogen, 655nm em. Q-
dots). Here it can be seen from panel A to panel B that cells adhere over the course of the 
10 minutes that the tissue is observed.  
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Figure 3.9. Rolling Velocities of EPCs on the following endothelial monolayer types 
[from left to right]: normoxic ECs, hypoxic ECs, EPC monolayer, and EC rolling 
velocities on an EC monolayer [control]. * p<0.05 using a Student‟s T-test relative to 
normoxic endothelial monolayer control. 
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Figure 3.10. Images of an endothelial monolayer injury model with the endothelial cells 
labeled in green (525nm em. Q-dots) and recruited and adhering EPCs labeled in red 
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Figure 3.11 is more specific in describing the rolling velocities of EPCs and mature ECs 
over both the injured and noninjured tissue. There was no significant decrease in the 
rolling velocities of the ECs. However, EPCs showed decreased velocities in comparison 
to ECs on both types of tissue, and a significantly slowed velocity on the injured 
endothelium with a rolling velocity nearly half that on the noninjured tissue. 
 
3.4 Discussion 
  
Ultimately these studies demonstrate the utility of a parallel plate flow chamber 
method for analyzing the homing capabilities of EPCs. As an in vitro model system for 
the luminal surface of blood vessels, it can be used to study EPC homing and recruitment 
in a number of organ systems and disease processes including, atherosclerosis, vascular 
complications of diabetes and retinopathy. Several of the experiments also show the 
importance of the CXCR4 receptor in the recruitment of EPCs to injured tissues as has 
been reported by several studies in the literature. Furthermore, when this receptor was 
blocked, there was decreased binding of the EPCs to the HA + SDF-1 coated surface. 
Further studies are needed to block this receptor in the hypoxia and scratch endothelial 
injury models to further test this receptor‟s contribution to EPC homing. 
 The assays of cellular adherence to ECM-coated surfaces proved EPCs to be 
superior to mature ECs at adherence to the ECM as well as to the specific antigen SDF-1. 
This is crucial since this antigen has been shown to be upregulated in hypoxia-injured 
tissues such as those in ocular disorders like DR and AMD. Testing further 
subpopulations against this antigen as well as through blockade of their defining surface 
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Figure 3.11. Analysis of adherence of EPCs and ECs to an endothelial monolayer injury 
model divided by either injured or noninjured portions of the tissue. * p<0.05 using a 
Student‟s T-test relative to noninjured endothelial progenitor cell control. 
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antigens should help determine the full extent of the homing mechanism of EPCs and 
how the various subpopulations interact with one another. 
 It is also very crucial that there was increased recruitment and slowed rolling 
velocity of EPCs to the hypoxic endothelial monolayers and scratch injured endothelial 
tissue. The slowed velocity suggests that there would be increased adherence of these 
cells over time. Quantum dots were an invaluable help in these injury models because the 
bright fluorescence allowed the cells to be captured in motion and the color allowed the 
different types to be distinguished. This will be of further help in future experiments, 
where multiple subpopulations will be added to the parallel plate flow chamber at once. 
There was a slowed adherence of EPCs on the EC monolayer in comparison to the ECM-
coated surfaces most likely due to decreased access to “recruiting antigens” like SDF-1 
and ECM components on the EC monolayer. This is expected since these cells would not 
adhere to a healthy vessel lumen. 
  Further studies using these models will help to expand the understanding of the 
specific role of individual EPC subpopulations within CNV. Pharmacological 
manipulation as well as the incorporation of isolated EPC subpopulations into the models 
will also facilitate further understanding of EPC involvement in ocular diseases as well as 
how these cells can be used to deliver preventative therapeutics to specific neovascular 
regions. The method outlined here for the flow chamber injury models will be invaluable 
in these studies, allowing for the simultaneous observation of several subpopulations and 
their interactions in an environment that is relevant to the disease state being studied, 
easy to manipulate, and relatively easy to replicate quickly. 
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CHAPTER IV 
 
IN VITRO SYSTEMIC ANALYSIS OF ENDOTHELIAL PROGENITOR CELL 
SUBPOPULATION NEOVASCULAR CAPACITIES 
 
4.1 Introduction 
 
A number of blinding ocular conditions are characterized by angiogenesis, 
including diabetic retinopathy, macular degeneration, retinopathy of prematurity, and 
vein occlusion retinopathy to name a few. The ocular angiogenesis and 
neovascularization of diabetic retinopathy (DR) and age-related macular degeneration 
(AMD) cause the greatest blindness in working-aged Americans and individuals 65 years 
or older in developed countries(67, 68). A number of factors including proteins, lipids and 
cellular interactions contribute to the pathology seen in these disorders. In 1997, Asahara 
and coworkers discovered a circulating population of cells originating from the bone 
marrow termed endothelial progenitor cells (EPCs) that have been shown to be recruited 
to neovascular lesions and to contribute to the vascular components of a variety of 
diseases including DR and AMD(2-4, 54). 
EPCs have been characterized by a number of cell surface antigens and 
distinguishing activities. A strong component of the “homing” ability of these cells has 
been linked to a chemokine receptor (CXCR4) on the surface of EPCs. The ligand for 
CXCR4, SDF-1 (stromal-derived factor-1), is increased in neovascular lesions and 
thought to attract EPCs to developing neovascular areas.7 These cells have also been 
isolated by the surface antigens CD133 and CD34, which are glycoproteins found 
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specifically on stem and progenitor cells(57-59). Takayuki Asahara, who is cited for first 
isolating and describing a population of EPCs, describes CD34 and Tie2 as important 
antigenic determinants of EPCs involved in postnatal vasculogenesis and 
neovascularization(69). EPCs have also been found to roll along and adhere to the 
endothelial cells of the inner vascular wall of neovascular tissue(55, 56). Relatively little 
is understood about the interactions of these characteristic surface antigens and there 
potential roles in the recruitment of EPCs to specific vascular lesions and tissues. The 
studies in this report have sought to better define the EPC cell populations that are 
involved in the angiogenesis and neovascularization that is seen in retinopathies. In 
further efforts to define and compare EPC subpopulations, novel in vitro methods were 
also used to model EPC homing capacities and the ability to influence endothelial cell 
capillary formation. 
Bone marrow-derived endothelial progenitor cells (EPCs) play a significant role 
in the neovascular component of retinal diseases such as diabetic retinopathy and age-
related macular degeneration. A variety of cell surface antigens have been shown to 
modulate this neovascular capacity, but little is known about the potential synergistic or 
competitive roles of these subpopulations in ocular pathology. This study sought to 
evaluate and compare different EPC subpopulations in tube formation and proliferation 
assays, under conditions relevant to ocular disease. Bone marrow was isolated from 4-6 
week-old Brown Norway rats. EPC subpopulations were identified by fluorescence-
activated cell sorting, using antibodies directed against CD34, CD133, Tie2 and CXCR4. 
Distinct EPC subpopulations were labeled with quantum dot-conjugated acetylated LDL, 
and mature endothelial cells (ECs) were labeled with Qtracker®. Tube formation and 
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proliferation assays were used to compare ECs and EPC subpopulations under conditions 
of VEGF or serum induction. CD34+/CD133+ cells demonstrated increased tube 
formation relative to ECs in serum-free, VEGF and 10% serum-stimulated conditions; 
tube formation was increased 612% (p<0.001), 78% (p<0.01) and 67% (p<0.01), 
respectively. Tie2+/CD133+ cells also demonstrated increased tube formation in VEGF 
and serum-stimulated conditions relative to ECs; tube formation increased 43% (p<0.05) 
and 22% (p<0.05), respectively. The proliferative capacity of CD34+/CD133+ cells was 
greatest, with a 70% (p<0.01) increase in VEGF-induced proliferation and a 44% 
increase in serum-induced proliferation, relative to ECs. Compared to EC controls, 
Tie2+/CD133+ cells demonstrated a 38% reduction (p<0.05) in VEGF-induced 
proliferation, while the Tie2-/CD133+ population demonstrated a 17% reduction in 
serum-induced proliferation. We have shown various EPC populations to exhibit 
different neovascular responses using two in vitro models of retinal angiogenic cell 
behavior. In both assays, the CD34+/CD133+ cells demonstrated the greatest neovascular 
capacity, suggesting that this EPC population may provide the greatest contribution to 
retinal disease. These results emphasize the importance of characterizing the angiogenic 
capacity of diverse EPC subpopulations in retinal vascular disease, as the knowledge may 
lead to better-targeted therapies for ocular diseases. 
 
4.2 Experimental Procedures 
 
4.2.1 Western Blot Analysis 
All animal procedures used in this study were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee and were performed in 
52 
 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. Litters of Sprague-Dawley rat pups and their mothers (Charles River 
Laboratories, Wilmington, MA) were transferred within 4 hours of birth to oxygen 
exposure chambers, where they received alternating 24-hour periods of 50% oxygen and 
10% oxygen for 14 days(70, 71). On postnatal day (P) 14, the oxygen-exposed rats were 
returned to room air. From P14 until six days after removal to room air, on P20, rats were 
sacrificed, and their retinas were removed and collected for protein analysis.  
For Western blot analysis, the retinas of three eyes were pooled in 300 μL cold 
lysis buffer (150 mM NaCl, 1.0% TritonX-100, 0.1% SDS, 50 mM Tris-HCl, 100 μg/mL 
PMSF, 1 mM orthovanadate, 0.3 μg/mL EDTA, 0.5% deoxycholate acid, 50 μΜ NaF, 0.5 
μg/mL leupeptin, 0.7 μg/mL pepstatin A, and 1.0 mg/mL aprotinin) and homogenized by 
sonication at 4°C. The samples were incubated at 4°C for 30 minutes and then 
centrifuged at 5000 rpm for 15 minutes at 4°C. Protein concentrations of the supernatants 
were determined with the BCA kit (Pierce). The volume of each sample was adjusted to a 
protein concentration of 2.5 μg/μL with cold lysis buffer containing protease inhibitors. 
Twenty microliters (50 μg) was mixed with 20 μL of 2× Laemmli buffer (Sigma, St 
Louis, MO) and heated at 95°C for 10 minutes. The samples were resolved by SDS-
PAGE and were transferred to 0.2 μm nitrocellulose membranes (Bio-Rad). 
Nitrocellulose membranes were blocked with TBST-1% bovine serum albumin (Sigma) 
and were probed with primary antibodies. Either goat anti-mouse IgG HRP (Chemicon, 
Temecula, Ca), goat anti-rabbit IgG-HRP (Chemicon), or donkey anti-goat IgG-HRP 
(Santa Cruz Biotechnology, Santa Cruz, CA) secondary antibodies were applied to the 
membranes and were developed with enhanced chemiluminescence (ECL; Amersham, 
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Piscataway, NJ). The following primary antibodies were used in this study: anti-CXCR4 
(Neuromics), anti-SDF-1 (Santa Cruz Biotechnology) and anti–CD34 (Santa Cruz 
Biotechnology); anti–CD105 (NeoMarkers) and anti-CD133 (Santa Cruz Biotechnology); 
anti-Tie2 (BD Pharmagen Biosciences). Each Western blot was repeated at least three 
times. 
 
4.2.2 Cell Isolation and Preparation 
 Cells were isolated from six, four- to six-week-old Brown Norway rats. The 
animals were sedated with methoxyflurane vapors, and then euthanized by decapitation. 
Their tibias and femurs were removed, and the bone marrow was isolated from these 
bones. The marrow tissue was then triturated and then the remaining cells were washed 
once with erythrocyte-lysing solution (154mM NH4Cl, KHCO3 10mM, EDTA 82M) by 
centrifugation. The cells were then washed three times by centrifugation with phosphate 
buffered saline to remove extracellular matrix debris. At this point, the cells were further 
isolated and characterized into subpopulations by FACS as described in section 4.2.3. 
These individual cell mixtures were then plated onto plastic dishes and grown in EGM-2 
media (Clonetics) containing 10% fetal bovine serum, 1ug/ml hydrocortisone, 10ng/ml 
epidermal growth factor and 5ml/500ml of 100X antibiotic/antimycotic solution (Sigma) 
for one full passage before use in vitro or labeled directly and used in the FACS assay to 
confirm the lack of significant surface antigen drift. 
 In order to label these cells with QD-acLDL or Qtracker (Invitrogen), the cells 
were incubated with 2ug/ml of QD-acLDL or 1ug/ml of Qtracker (as directed) for four to 
six hours, then removed from the dish using Accutase
TM
 (Sigma) followed by 
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centrifugation and resuspension to the desired concentration in PBS before use in the in 
vitro assays. 
 
4.2.3 Fluorescence Activated Cell Sorting (FACS) 
For all of the surface antigens investigated, isolated bone marrow was taken from 
the rats as described above and incubated in a 200 g/ml of the appropriate blocking IgG 
for 10 minutes in an ice bath. A 1:500 dilution of the unconjugated primary antibody was 
then added to the solution. The antibodies used were anti-CXCR4 (Santa Cruz), anti-
CD133 (Abcam and Santa Cruz) and anti-CD34 (Abcam). Appropriate non-labeled 
controls were set aside at this time as well. This suspension was incubated on ice for 
another 15 minutes. The cells were centrifuged at 1500×g for 3 minutes at 4°C and then 
resuspended in a 1:2000 dilution of the secondary antibody (Jackson Labs) conjugated to 
quantum dots (em. 655 and 525) using an the Invitrogen antibody conjugation kit. This 
solution was also incubated 15 minutes in an ice bath. The cells were then centrifuged for 
3 minutes at 1500×g and 4°C. The cells were sorted on a 3-laser BD LSRII cell sorter 
(BD Biosciences) at the Vanderbilt Flow Cytometry Core. 
 
4.2.4 In Vitro Parallel Plate Flow Chamber (PPFC) Assay 
 PPFC and Hypoxic Endothelial Monolayer Adherence assay 
 Cells grown in culture and labeled with either QD-acLDL or Qtracker were using 
at 1-2 X 10
6 
cells/ml. The cells were placed into a parallel plate flow chamber (PPFC) 
(Glycotech Corporation). The chamber used has a flow width of 1.00cm and a height of 
0.010 in. Throughout these studies, a flow rate consistent with a shear stress of 15 
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dynes/cm
2 
was used. Slides in these experiments had a confluent monolayer of 
endothelial cells on their surface. These cells were either mature endothelial cells 
cultured under normoxic conditions or hypoxic conditions for 24 hours prior to their use 
in the PPFC. Monolayers of EPCs were also used. The slides were assembled as the 
lower wall of the PPFC and mounted on the stage of an inverted microscope. Images 
were captured of the flowing cells every 300ms for 5 to 15 minutes and cell counts and 
rolling velocities were determined at frequent time points using Image Pro-Plus tracking 
software.  
 
4.2.5 Proliferation and Tube Formation Assays 
Rat endothelial progenitor cells as well as rat retinal microvascular endothelial 
cells (RRMECs) were seeded in 10% serum EBM at 3000 cells/well in a 96-well plate 
and were allowed to attach and settle. The cells were serum-starved for 12 hours and then 
treated with 1% serum medium in the absence or presence of 50 ng/mL VEGF. Cells 
were then labeled with BrdU for 12 hours, and BrdU incorporation was quantified with a 
colorimetric ELISA (Roche, Indianapolis, IN) according to the manufacturer's 
instructions. The experiment was independently repeated three times. 
Twelve-well tissue culture plates were coated with 200 μL growth factor-reduced 
basement membrane matrix (Matrigel; Becton Dickinson, Franklin Lakes, NJ). RRMECs 
labeled with 525nm Qtracker (Invitrogen) were seeded at 20,000 cells/well and treated 
with serum-free EBM alone, EBM containing 50ng/ml VEGF, or 10% serum. The cells 
were cultured for 4 hours at 37°C in a 5% CO2 atmosphere to allow tubes to begin to 
form. Then mature endothelial cells or specific subpopulations of EPCs were added at 
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20,000 cells/well and kept in culture for 12 hours more. Tubes were observed with an 
IMT-2 inverted microscope (Olympus, Melville, NY), and images were captured with a 
DMC digitizing camera (Polaroid Corporation, Waltham, MA). Six fields per well were 
captured for quantitative analysis. The digitized images were imported into ImageJ 
software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; 
available at http://rsb.info.nih.gov/ij/index.html). Capillary-like structures of more than 
two cell lengths were assessed, and the mean tube length per field of each well was 
calculated. The average tube length of each treatment group was reported. The 
experiment was independently repeated three times. 
 
4.3 Results 
 
4.3.1 Assessment of Rat Oxygen-Induced Retinopathy (OIR) Tissue for EPC-
Associated Antigens 
CXCR4 is the chemokine receptor for SDF-1 and was highly expressed on the 
surface of bone marrow-derived cells relative to cells resident to the retina. This receptor 
has also been implicated in the majority of the homing ability of EPCs. In the retinal 
tissue of OIR model rats, CXCR4 levels were elevated 1.8-fold when the animals were 
initially removed from treatment (having most recently came from an environment of 
10% oxygen) and 2.5- and 2.1-fold, respectively, at three and six days following removal 
of the animals from oxygen treatment. These times are associated with the initial onset 
and peak neovascular growth in these animals (Figures 4.1 and 4.2). CD133 is a cell 
surface marker expressed by undifferentiated stem/progenitor cells and is quickly lost 
after cell differentiation. Similarly to CXCR4, at post-treatment days three and six, 
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CD133 levels were elevated 4.5-fold relative to earlier time points in the oxygen-treated 
samples and every time point in comparison to the room air-raised control animals 
(Figures 4.1 and 4.2). 
SDF-1 is a chemokine that binds exclusively to CXCR4, attracting cells that 
express this receptor. In the retinal tissue of oxygen treated animals, there were elevated 
levels of SDF-1 that closely corresponded to those of CXCR4 appearing to precede that 
of the receptor by about a day, however, the SDF-1 levels were much more strongly 
elevated to 5-fold levels relative to earlier time points in the OIR tissue and all room air-
raised samples (Figures 4.1 and 4.2). 
CD34 is a glycoprotein cell surface receptor that has been shown to be expressed 
on the surface of many progenitor and stem cells, and was the original antigen used to 
identify EPCs by Asahara et al.(2) Tie2 was also suggested in this initial manuscript 
describing EPCs as well as later manuscripts(69) by this group as being an important 
determinant of EPCs involved in vasculogenesis.  This analysis, however, found no 
significant differences in the levels of either of these proteins when comparing any of the 
time points or either of the treatments (Figure 4.2). 
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Figure 4.1. Western blots showing EPC-associated antigens at several time points in 
post-oxygen treated retinal tissue from OIR and room air-raised control animals. Samples 
in every lane were matched for protein concentration and ultimately compared to one 
another after being normalized to relative beta-actin levels. 
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Figure 4.2. This shows the normalized and averaged results of the Western blot protein 
quantities for the EPC-associated antigens shown in Figure 4.1. Each protein was 
normalized to beta-actin and every Western blot was independently repeated at least three 
times. An “*” indicates a significance level of p<0.05, and a “†” indicates a significance 
level of p<0.02. 
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4.3.2 Assessment of EPC Homing and Recruitment in a Hypoxic Endothelial 
Monolayer Adherence Model 
This assay is meant to model the adherence of circulating EPCs in the vascular 
system to the luminal wall of blood vessels in healthy and in hypoxic tissue. In this set of 
experiments, EPCs are propelled over a surface of endothelial cells in a monolayer 
culture and assessed for recruitment to this monolayer by reduced rolling velocities. 
Figure 4.3 illustrates the assessment of EPCs labeled with Qtracker (Invitrogen, 655nm 
emission Q-dots) adhering and rolling on an endothelial monolayer also labeled with a 
different wavelength quantum dot (525nm em. Q-dots). The monolayers tested were 
either cultured in normoxic conditions or in hypoxia (<1% oxygen for 24 hrs). The cells 
that were flowing in suspension in the parallel plate flow chamber (PPFC) were mature 
endothelial cells, a heterogeneous EPC population and the CD133+/CD34+ 
subpopulation of EPCs. 
The findings in Figure 4.3 demonstrate the lack of adherence or very slight 
adherence of mature endothelial cells to themselves. This adherence was unaffected by 
the treatment of the endothelial monolayer in hypoxia. The heterogeneous EPC 
population (Hetero. EPC), shows greater adherence to the endothelial monolayer under 
normoxic conditions relative to the mature endothelial cells, and the hetero. EPCs 
demonstrated significantly decreased rolling velocities (16%, p<0.05) relative to the 
velocity of these cells on normoxic-treated (20.9% oxygen) monolayers. The 
CD133+/CD34+ subpopulation of EPCs, however, showed an even greater decrease in 
rolling velocity (40%, p<0.02) relative to the velocity of these cells on normoxic treated 
monolayers. There was no significant difference between the rolling velocities of the 
EPC populations on normoxic treated endothelial monolayers. 
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Figure 4.3. The homing ability of EPCs is tested in a parallel plate flow chamber using 
endothelial monolayers that have been exposed to 24 hours of hypoxia or normoxia 
immediately before the assay begins. Rolling velocities of the cells are measured and a 
slower rolling velocity is indicative of increased adherence to the endothelial monolayer. 
The graph to the left is the average accumulated distance of the cells at each time point 
during the assay and the graph to the right shows the average rolling velocity of each cell 
type for the entire assay. An “*” is indicative of a significance level of p<0.05, and a “†” 
indicates a significance level of p<0.02. 
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4.3.3 VEGF- and Serum-Mediated Endothelial Cell Capillary Tube Formation 
Influence by EPC Subpopulations 
This assay should model the effect that homing EPCs would have on endogenous 
endothelial cells that are proliferating and forming new capillary networks in angiogenic 
or neovascular tissue. The first column of Figure 4.4 shows that endothelial cells alone 
do not respond by forming tubes in an environment that is free of serum, but have 
progressively increased responses with VEGF and serum treatment. The second column 
depicting the addition of a hetero. EPC population to the endothelial cells shows a slight 
increase in tubes being formed in the serum free panel. There is also a similar capacity 
for tube formation in the VEGF-stimulated row of this column, however, an apparent 
increase in tube formation in the serum stimulated panel relative to the mature endothelial 
cells alone. This heterogeneous population of cells seems to cause more clumping of the 
endothelial cells as they are forming tubes, however, a majority of the tubes seem to be 
formed by the green-labeled endothelial cells and not the red-labeled EPCs. The right 
column of the panel shows the addition of CD133+/ C34+ EPCs to the endothelial cells 
forming tubes. This EPC subpopulation demonstrates a strong clumping effect on the 
endothelial cells in the serum free panel incorporating themselves into these clumps. The 
EPCs in this column also demonstrate an increased tube formation influence on the 
endothelial cells in both the VEGF- and serum-stimulated panels. With both stimuli, the 
red-labeled EPCs are shown forming tubes as frequently as the green-labeled EPCs. 
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Figure 4.4. These panels show the varied qualitative responses of the mature endothelial 
cells and EPCs in a tube formation assay stimulated with either 10% serum or 50ng/ml 
rat VEGF. In these experiments the mature endothelial cells were prelabeled with a green 
fluorescent tracker and the EPC subpopulations were labeled with a red fluorescent 
tracker. 
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Figure 4.5 shows a graphically quantified representation of the panels in Figure 
4.4. Again, relative to the endothelial cell controls, the heterogeneous population of the 
whole bone-marrow cells was more varied with a potentially decreased response to 
VEGF and an increased response to serum. The CD133+/CD34+ cells, however, 
demonstrated a strong and significant influence to increase tube formation of the 
endothelial cells in serum free, VEGF-stimulated and serum stimulated conditions. This 
population of EPCs had a 6.5-fold increase on the tube length in serum free conditions 
and a 1.7-fold increase on tube length in both VEGF- and serum-stimulated conditions. 
Tie2+/CD133+ cells were also used in this assay and did demonstrate a slightly increased 
and significant tube formation effect of 1.4-fold in both of the stimulated conditions. This 
subpopulation, however, did have any effect on the formation of tubes by the endothelial 
cells in the unstimulated (serum free) condition. 
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Figure 4.5. The graph shows the quantified tube lengths of the tube formation assay 
demonstrated in the Figure 4.4 panels. In this assay the tube lengths were normalized to 
the mature endothelial cell response to VEGF stimulation. An “*” indicates a significance 
of p<0.05. 
 
  
* 
* 
* 
* 
* 
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4.3.4 VEGF- and Serum-Mediated Proliferation of EPC Subpopulations 
 In Figure 4.6, the proliferation experiments showed a nearly 2-fold response of 
the control, mature endothelial cells and an even more robust 4-fold response of these 
cells to 10% serum. Of the EPC populations tested, the CD133+/CD34+ cells had the 
strongest proliferation in all of the treatments. These cells grew nearly 20% more in 
conditions without serum, but, additionally, had a 3-fold increase (p<0.01) in 
proliferation in response to VEGF and a 5-fold increase (p<0.01) in proliferation in 
response to the serum treatment. It is interesting to note that the Tie2+/CD133+ cells had 
an enhanced response to VEGF stimulated proliferation relative to mature endothelial 
cells, but did not have a statistically different response when stimulated with 10% serum. 
The heterogeneous population of EPCs had a decreased response to both proliferative 
stimuli and higher variability that is presumed to be the result of varied cell populations 
within this group and their respectively varied capacity to respond to the proliferative 
stimulants. 
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Figure 4.6. Analysis of EPCs subpopulation proliferation. An “*” indicates p<0.01 
relative to mature ECs and p<0.02 from all other cell types; a “†” indicates a p<0.05 
relative to mature ECs.  
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4.4 Discussion 
Ultimately these studies show the importance of the CD133+/CD34+ 
subpopulation of EPCs in the homing, proliferation and tube formation models that have 
been tested. This subpopulation has consistently outperformed mature endothelial cells as 
well as a heterogeneous population of EPCs in all three assays. The CD133+/CD34+ 
subpopulation has also proven itself to be more influential than the CD133+/Tie2 
subpopulation of cells in the proliferation assay as well as the tube formation assay. This 
demonstrates the potential of this cell population in the progression and exacerbation of 
the types of neovascular lesions that are seen in retinopathies. However, the 
CD133+/CD34+ subpopulation could be more thoroughly tested, and the EPC-associated 
antigens that were analyzed in Figures 4.1 and 4.2 indicate some subpopulations to test 
against CD133+/CD34+ cells. 
 The Western blot protein analysis of EPC-associated antigens revealed the 
stem/progenitor cell antigen, CD133 and the antigen associated with cells originating 
from the bone marrow, CXCR4, both present in the retinal tissue at increased 
concentrations at times of peak neovascular proliferation. This suggests that progenitor 
cells from the bone marrow are in the retina during this time and may be involved in this 
neovascular proliferation. While CD34 and Tie2 were not found to change during these 
time points or between treatment groups, they are antigens found on proliferating 
endothelial cells. The overwhelming levels of these proteins on the endogenous 
endothelial cell populations may overwhelm any additional quantities that would be 
added by EPCs homing to these neovascular sites. However, the in vitro experiments in 
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this study have outlined a clear difference between the subpopulation of EPCs isolated 
with CD34 and those isolated with Tie2.  
 Additionally, it may be useful to continue using the western blot analysis 
screening method for several more promising antigens. If neither of these ligand/receptor 
pair antigens are present in the retinal tissue, they could be more easily dismissed as 
unlikely to be involved in this process. CD44, c-kit, and VEGFR3 should still be 
examined in OIR and room air-raised tissue. 
 With another subpopulation or two for comparison, the in vitro assays will carry 
much more meaningful results. These legitimate head to head comparisons of the 
subpopulations will help to identify the subpopulations that have the greatest involvement 
and influence in retinal neovascularization. Then these subpopulations can be validated 
and manipulated within animal models. 
 Further studies using these in vitro models will help to expand the understanding 
of the specific role of individual EPC subpopulations within retinal neovascular lesions. 
Pharmacological manipulation as well as the incorporation of isolated EPC 
subpopulations into the models will also facilitate further understanding of EPC 
involvement in ocular diseases as well as how these cells can be used to deliver 
preventative therapeutics to specific neovascular regions. The method outlined here for 
the influence of endothelial capillary tube formation will be invaluable in these studies 
along with the homing assay. These assays could allow for the simultaneous observation 
of several subpopulations and their interactions in an environment that is relevant to the 
aspects of the hypoxic and neovascular tissue of the diseased retina. The assays are easy 
to manipulate, and relatively easy to replicate quickly. There were several more aspects 
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of the tube formation assay that could have been measured such as the percentage of 
tubes that were formed by the mature endothelial cells relative to the EPCs or the length 
of the EPC tubes to those of the mature endothelial cells within the same treatment 
groups. These aspects of this assay will be addressed in future experiments. 
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CHAPTER V 
 
BLOCKING ENDOGLIN REDUCES ENDOTHELIAL PROGENITOR CELL 
ANGIOGENIC CAPACITY AND RETINAL NEOVASCULARIZATION 
 
5.1 Introduction 
 
Angiogenesis and neovascularization are common pathological processes in age-
related macular degeneration and retinopathies. Endoglin (CD105) has been reported as 
being upregulated in proliferative tumor vasculature and neovascular tissues. As an 
acillary receptor in the TGFβ super family it is suggested to be involved in cell 
proliferation, migration and differentiation. This study sought to examine the role of 
endoglin in endothelial progenitor cell (EPC) angiogenic capacity and retinal 
neovascularization. Endoglin was characterized and effectively blocked in models of 
endothelial progenitor cell homing, capillary tube formation and incorporation, and 
proliferation. Additionally endoglin was blocked in a rat model of oxygen induced 
retinopathy (OIR). Endoglin protein was found to be upregulated in OIR tissue relative to 
animals raised in room air conditions. This increase in endoglin could be reduced through 
the treatment of the animals with a CXCR4 antagonist (AMD3100) to inhibit the ability 
of EPCs home to neovascular areas. Endoglin targeted treatments were additionally able 
to inhibit both EPC proliferation and tube formation. However, EPC in vitro homing was 
unaffected by anti-CD105 treatment. The anti-CD105 was found to be effective in 
reducing the neovascular lesion size in the OIR model and worked additively with anti-
VEGF treatments. Endoglin has an angiogenic role in retinal neovascularization and 
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blocking endoglin function is an effective method of reducing neovascularization 
partially through a reduced angiogenic capacity of EPCs. 
Angiogenesis, the formation of new capillaries from existing blood vessels, 
occurs during physiologic processes such as reproduction, growth and development, and 
wound healing(72-77). Conversely, diseases such as arthritis, tumor growth and 
retinopathies are characterized by pathological, persistent angiogenesis(77-79). In the 
context of the retina, pathological, persistent angiogenesis is often referred to as retinal 
neovascularization (NV). Age-related macular degeneration (AMD), diabetic retinopathy 
(DR), and retinopathy of prematurity (ROP) are potentially blinding conditions 
characterized by choroidal or retinal NV. 
 The neovascularization that is seen in all of these ocular diseases is widely viewed 
to be driven primarily by vascular endothelial growth factor (VEGF)(80-82). As a result 
of this common vasoactive factor, the current pharmacologic therapies used clinically 
target VEGF(83, 84). Bevacizumab (Avastin, Genentech) and Ranibizumab (Lucentis, 
Genentech) are humanized monoclonal antibodies with high affinities for VEGF-A. As 
useful and efficacious as these therapies have been there are still concerns about their use 
and patients that do not improve with VEGF targeted therapy. There are concerns about 
anti-VEGF therapies leaking into the serum and circulatory system potentially damaging 
unintended vascular systems, particularly in younger patients(85). Additionally, there is 
evidence that VEGF plays an important survival role for neurons(86, 87). This could 
mean neuronal damage with prolonged VEGF targeted therapy. When visual outcome is 
the analyzed parameter in studies using VEGF targeted therapies, as many as 45% of the 
patients were found to be nonresponsive to the treatment(88, 89). With these concerns in 
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mind, it would be useful to have non-VEGF pathway therapies to target in ocular 
neovascularization. 
 Endoglin (CD105) is a potential non-VEGF pathway protein that could be 
targeted in the treatment of neovascularization. It is a transmembrane glycoprotein that is 
an accessory to the transforming growth factor β (TGFβ) receptor system(18).  Endoglin 
is also expressed on proliferating endothelial cells (ECs) and tumor types characterized 
by hypoxia(19-24). On endothelial and tumor cells, it is thought to be involved in 
differentiation, migration and proliferation(20, 25). Monoclonal antibody therapies have 
been shown to have some antiproliferative effects in cancer studies(26, 27). Furthermore, 
subsets of endothelial progenitor cells (EPCs) have been found to highly express 
CD105(28-30). Additionally, as marker of mesenchymal stem cells, endoglin has been 
shown on progenitor cells that increase vascular remodeling in models of myocardial 
infarction and rheumatic diseases(31, 32).Many investigators suggest that EPCs play a 
significant role in ocular neovascularization and that these cells could be targeted to 
influence that neovascularization(33, 34). Perhaps targeting EPCs through CD105 could 
prevent their differentiation and proliferation in the neovascular lesions seen in the 
angiogenic pathology of the eye. 
In these studies, the role of endoglin in EPC angiogenic capacity and retinal 
neovascularization was explored. By analyzing mature ECs and EPCs for CD105 in 
models of neovascular conditions, we sought to determine any connections between 
developing neovascularization and endoglin. Then through in vitro modeling of the 
homing, capillary incorporation and proliferation capabilities of EPCs, the effect of 
endoglin blockade on EPC function could be determined. Finally, we examined the effect 
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of blocking endoglin in a model of oxygen-induced retinal neovascularization. These 
experiments were performed concomitantly with anti-VEGF therapy in order to directly 
compare the two different strategies.  
 
5.2 Experimental Procedures 
 
5.2.1 Cell Isolation and Preparation 
 Cells were isolated from six, four- to six-week-old Brown Norway rats. The 
animals were sedated with methoxyflurane vapors, and then euthanized by decapitation. 
Their tibias and femurs were removed, and the bone marrow was isolated from these 
bones. The marrow tissue was then triturated and then the remaining cells were washed 
once with erythrocyte-lysing solution (154mM NH4Cl, KHCO3 10mM, EDTA 82M) by 
centrifugation. The cells were then washed three times by centrifugation with phosphate 
buffered saline to remove extracellular matrix debris. At this point, EPC subpopulations 
were further isolated and characterized first by immunopanning for cells expressing 
CD133 and then by FACS for CD34+ cells as described in section 4.2.3. These individual 
cell mixtures were then plated onto plastic dishes and grown in EGM-2 media (Clonetics) 
containing 10% fetal bovine serum, 1ug/ml hydrocortisone, 10ng/ml epidermal growth 
factor and 5ml/500ml of 100X antibiotic/antimycotic solution (Sigma) for one full 
passage before use in vitro or labeled directly and used in the FACS assay to confirm the 
lack of significant surface antigen drift. 
 In order to label these cells with QD-acLDL or Qtracker (Invitrogen), the cells 
were incubated with 2ug/ml of QD-acLDL or 1ug/ml of Qtracker (as directed) for four to 
six hours, then removed from the dish using Accutase
TM
 (Sigma) followed by 
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centrifugation and resuspension to the desired concentration in PBS before use in the in 
vitro assays. 
 
5.2.2 Fluorescence Activated Cell Sorting (FACS) 
For all of the surface antigens investigated, isolated bone marrow was taken from 
the rats as described above and incubated in a 200 g/ml of the appropriate blocking IgG 
for 10 minutes in an ice bath. A 1:500 dilution of the unconjugated primary antibody was 
then added to the solution. The antibodies used were anti-CD34 (Abcam). Appropriate 
non-labeled controls were set aside at this time as well. This suspension was incubated on 
ice for another 15 minutes. The cells were centrifuged at 1500×g for 3 minutes at 4°C and 
then resuspended in a 1:2000 dilution of the secondary antibody (Jackson Labs) 
conjugated to quantum dots (em. 655 and 525) using an the Invitrogen antibody 
conjugation kit. This solution was also incubated 15 minutes in an ice bath. The cells 
were then centrifuged for 3 minutes at 1500×g and 4°C. The cells were sorted on a 3-
laser BD LSRII cell sorter (BD Biosciences) at the Vanderbilt Flow Cytometry Core. 
 
5.2.3 In Vitro Hypoxia Treatment 
EPCs that were isolated from bone marrow, according the procedure described 
sections 5.2.1 and 5.2.2. Cells from passages two to three were used in the following 
experiments. The cells were grown in EGM-2 media (Clonetics) containing 10% fetal 
bovine serum, 1ug/ml hydrocortisone, 10ng/ml epidermal growth factor and 5ml/500ml 
of 100X antibiotic/antimycotic solution (Sigma) to 70% confluence, and then maintained 
in normoxia for 24 hours. After 24 hours, cells were exposed to hypoxia for 18 hours 
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(using a BBL GasPakTM system; Becton, Dickinson and Company, Sparks, MD). Some 
cultures were lysed for Endoglin ELISAs, (Quantikine Colorimetric Sandwich ELISA; 
R&D Systems) while others were prepared for immunocytochemistry staining with anti-
CD105 (Millipore). These experiments were conducted four times, with n = 4 for each 
treatment group. 
 
5.2.4 Rat Oxygen Treatment 
All animal experiments were approved by the Vanderbilt University School of 
Medicine Animal Care and Use Committee, and they were conducted according to the 
principles expressed in the ARVO statement for the Use of Animals in Ophthalmic and 
Vision Research. Within 4 hours after birth, litters of Sprague-Dawley rat pups and their 
mothers were exposed to alternating periods of 24 hrs at 50% and10% oxygen, for 14 
days. This variable oxygen treatment protocol predisposes the rat pups to OIR. Hereafter, 
these rats are referred to as OIR rats. Age-matched control rats were maintained in 
ambient (20.9% oxygen) normoxia. These rats are referred to as room air (RA) rats. After 
the variable oxygen treatment, the OIR rats were returned to room air for up to six days, 
allowing time for retinal NV to develop. We refer to the timing of sacrifice and 
assessment with two numbers, one representing the time in variable oxygen and one 
representing the post-exposure period. Hence, rats sacrificed immediately upon removal 
from exposure are termed 14(0), while rats sacrificed at the end of the six-day post-
exposure period are referred to as 14(6). 
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5.2.5 Western Blot Analysis 
For Western blot analysis, the retinas of three eyes were pooled in 300 μL cold 
lysis buffer (150 mM NaCl, 1.0% TritonX-100, 0.1% SDS, 50 mM Tris-HCl, 100 μg/mL 
PMSF, 1 mM orthovanadate, 0.3 μg/mL EDTA, 0.5% deoxycholate acid, 50 μΜ NaF, 0.5 
μg/mL leupeptin, 0.7 μg/mL pepstatin A, and 1.0 mg/mL aprotinin) and homogenized by 
sonication at 4°C. The samples were incubated at 4°C for 30 minutes and then 
centrifuged at 5000 rpm for 15 minutes at 4°C. Protein concentrations of the supernatants 
were determined with the BCA kit (Pierce). The volume of each sample was adjusted to a 
protein concentration of 2.5 μg/μL with cold lysis buffer containing protease inhibitors. 
Twenty microliters (50 μg) was mixed with 20 μL of 2× Laemmli buffer (Sigma, St 
Louis, MO) and heated at 95°C for 10 minutes. The samples were resolved by SDS-
PAGE and were transferred to 0.2 μm nitrocellulose membranes (Bio-Rad). 
Nitrocellulose membranes were blocked with TBST-1% bovine serum albumin (Sigma) 
and were probed with primary antibodies. Either goat anti-mouse IgG HRP (Chemicon, 
Temecula, Ca), goat anti-rabbit IgG-HRP (Chemicon), or donkey anti-goat IgG-HRP 
(Santa Cruz Biotechnology, Santa Cruz, CA) secondary antibodies were applied to the 
membranes and were developed with enhanced chemiluminescence (ECL; Amersham, 
Piscataway, NJ). The following primary antibodies were used in this study: anti–CD105 
(NeoMarkers). Each Western blot was repeated at least three times. 
 
5.2.6 Vascular and Immunohistochemical Staining 
 At post natal days 17 and 20, the eyes of the mice were removed, and retinal flat-
mounts were prepared by removing the cornea and lens in 10% phosphate-buffered 
78 
 
formalin. The retina was then dissected from the eyecup, and radial cuts were made from 
the edge of the eyecup in all four quadrants to the equator.  In these flat-mounts the 
endothelial cells were identified using Isolectin B4, FITC conjugate (Sigma-Aldrich, 
Inc.), and anti-CD105 (Millipore). The tissue was then flat-mounted in Gel Mount 
(Biomedia, Victoria, Australia). Areas of vascular and avascular growth were measured 
via computer-assisted image analysis using high-resolution digital images of the stained 
retinal flat-mounts. All measurements were made using tools in Adobe Photoshop CS 
(Adobe Systems Inc.). 
 
5.2.7 In Vitro Parallel Plate Flow Chamber (PPFC) Assay 
 PPFC and Hypoxic Endothelial Monolayer Adherence assay 
 Cells grown in culture and labeled with either QD-acLDL or Qtracker were using 
at 1-2 X 10
6 
cells/ml. The cells were placed into a parallel plate flow chamber (PPFC) 
(Glycotech Corporation). The chamber used has a flow width of 1.00cm and a height of 
0.010 in. Throughout these studies, a flow rate consistent with a shear stress of 15 
dynes/cm
2 
was used. Slides in these experiments had a confluent monolayer of 
endothelial cells on their surface. These cells were either mature endothelial cells 
cultured under normoxic conditions or hypoxic conditions for 24 hours prior to their use 
in the PPFC. Some cells were treated with anti-CD105 (Millipore) at concentrations 
ranging from 1-100 ug/ml for 10 minutes prior to and during their flow over the 
monolayers. An anti-rat IgG and AMD3100 (CXCR4 antagonist) were also used at 100 
ug/ml and 5 ug/ml, respectively, as controls in these experiments. The slides were 
assembled as the lower wall of the PPFC and mounted on the stage of an inverted 
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microscope. Images of the flowing cells were captured every 300ms for 5 to 15 minutes 
and cell counts and rolling velocities were determined at frequent time points using 
Image Pro-Plus tracking software.  
 
5.2.8 Proliferation and Tube Formation Assays 
Rat endothelial progenitor cells as well as rat retinal microvascular endothelial 
cells (RRMECs) were seeded in 10% serum EBM at 3000 cells/well in a 96-well plate 
and were allowed to attach and settle. The cells were serum-starved for 12 hours and then 
treated with 1% serum medium in the absence or presence of 50 ng/mL VEGF or 10% 
serum. On these back grounds some cells were also treated with anti-CD105 (Millipore) 
at concentrations ranging from 1-100 ug/ml or anti-VEGF at 100ug/ml (Sigma). Cells 
were then labeled with BrdU for 12 hours, and BrdU incorporation was quantified with a 
colorimetric ELISA (Roche, Indianapolis, IN) according to the manufacturer's 
instructions. The experiment was independently repeated three times. 
Twelve-well tissue culture plates were coated with 200 μL growth factor-reduced 
basement membrane matrix (Matrigel; Becton Dickinson, Franklin Lakes, NJ). RRMECs 
labeled with 525nm Qtracker (Invitrogen) were seeded at 20,000 cells/well and treated 
with serum-free EBM alone, EBM containing 50ng/ml VEGF, or 10% serum. The cells 
were cultured for 4 hours at 37°C in a 5% CO2 atmosphere to allow tubes to begin to 
form. Then mature endothelial cells or specific subpopulations of EPCs were added at 
20,000 cells/well and kept in culture for 12 hours more. On these back grounds some 
cells were also treated with anti-CD105 (Millipore) at concentrations ranging from 1-100 
ug/ml or anti-VEGF at 100ug/ml (Sigma). Tubes were observed with an IMT-2 inverted 
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microscope (Olympus, Melville, NY), and images were captured with a DMC digitizing 
camera (Polaroid Corporation, Waltham, MA). Six fields per well were captured for 
quantitative analysis. The digitized images were imported into ImageJ software 
(developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available 
at http://rsb.info.nih.gov/ij/index.html). Capillary-like structures of more than two cell 
lengths were assessed, and the mean tube length per field of each well was calculated. 
The average tube length of each treatment group was reported. The experiment was 
independently repeated three times. 
 
5.2.9 Intravitreal Injections 
Rats were anesthetized by isoflurane (TerrellTM; Meridian, ID) inhalation, and a 
single drop of 0.5% proparacaine (Allergan; Hormigueros, PR) was topically applied to 
the cornea prior to intravitreal injection. For all intravitreal injections, the globe was 
penetrated posterior to the ora ciliaris retinal using a 30-gauge needle with a 19° bevel 
and a 10 l syringe (Hamilton Co.; Reno, NV). The needle was advanced to the posterior 
vitreous while maintaining a steep angle to avoid contact with the lens. The injection 
bolus (5 l) was delivered near the trunk of the hyaloids artery, proximal to the posterior 
pole of the retina. Following injection, a topical antibiotic suspension (neomycin and 
polymyxin B sulfates and gramicidin; Monarch Pharmaceuticals; Bristol, TN) was 
applied. Non-injected eyes were also treated with topical proparacaine and antibiotic to 
control for the potential of these agents to influence retinal vessel growth. 
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5.2.10 Drug Treatment 
At 14(0), a time of high retinal VEGF expression in this model, eyes from OIR 
and RA rats remained uninjected, or were injected with 5 ul of vehicle (PBS), rat anti-
VEGF (sigma) at 1.0 mg/ml or anti-CD105 at doses ranging from 0.01-1.0 mg/ml. These 
doses were initially chosen based on published data for the use of anti-VEGF 
treatments(90, 91). 
 
5.2.11 Quantification of Retinopathy 
OIR rats were euthanized by decapitation on 14(6). Rats were enucleated and the 
neural retinas were dissected and placed in cmf-PBS with 10% formaldehyde solution 
(37% formaldehyde solution; Fisher Scientific Fair Lawn, NJ) overnight at 4 C. The 
retinal vasculature was stained for ADPase activity, according to a previously described 
method(92) adapted for use herein(70, 93). Images of ADPase-stained retinas were 
digitized, captured, and displayed at 20X magnification. The total retinal area and the 
retinal area containing blood vessels were traced on the monitor face. The number of 
pixels within these areas was converted to mm
2
. Measurements of this parameter were 
recorded. To determine the effect of the various treatments on pathological angiogenesis, 
the extent of retinal NV was assessed in flat-mounted retinas stained for ADPase activity. 
Representative retinal flatmounts quadrants are shown. Abnormal preretinal NV was 
assessed by digitally measuring NV area. Digitized images of the retinas were captured 
and displayed at 65X magnification. Preretinal vessels were then traced on a computer 
monitor. The pixels contained in the areas of NV were totaled for each retina and 
converted to mm
2
 (Photoshop CS; Adobe Systems Inc.). The operator was masked with 
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respect to the treatment. Where there was a question of the preretinal nature of a vessel 
tuft, the tissue was evaluated with a light microscope at 200X magnification using the 
plane of focus. This method of estimation correlates well (r
2
 = 0.947) with the clockhour 
method of estimation(94), and yields normally distributed data that allow statistically 
significant differences between treatment groups to be determined by analysis of 
variance. The retinas of age-matched RA rats showed no pathology and were not 
included in statistical analyses. 
 
5.2.12 Statistical Analysis 
Statistically significant differences between treatment and control groups 
throughout this study were determined by analysis of variance with a Dunnett‟s post hoc 
procedure p≤0.05 was considered significant. Unless otherwise stated, error bars on the 
graphs indicate standard deviation. Unless otherwise stated, each experiment was 
repeated three times. For each experiment, n = 8 – 12 eyes for each treatment group. 
 
5.3 Results 
 
5.3.1 In Vitro Protein Expression of Endoglin During Normoxia or Hypoxia 
 In this set of experiments, mature endothelial cells and EPCs were exposed to 24 
hours of either hypoxia or normoxia. There was very little positive immunocytochemical 
staining for CD105 in normoxic EPCs, however, there were a small number of cells that 
were clearly positive for the protein. Similarly, there was almost no positive CD105 
staining of the normoxic ECs and less in comparison to the normoxic EPCs. Having been 
affected by the hypoxic treatment, the hypoxic EPCs demonstrated a large upregulation 
83 
 
of CD105 protein expression; however, it stained more strongly on some cells than 
others. The hypoxic mature ECs also exhibited an increase in CD105 staining relative to 
normoxic ECs, but it is less than the hypoxic EPCs. The hypoxic mature EC CD105 
staining intensity was closest to that of the normoxic EPC staining. This is depicted in 
Figure 5.1. 
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Figure 5.1. Endoglin staining in CD133+/CD34+ EPCs and mature ECs treated for 
hypoxia and normoxia for 24 hours. Endoglin is shown in red while DAPI stained cell 
nuclei are shown in blue. A and B are CD133+/CD34+ EPCs. C and D are mature ECs. A 
and C are normoxia treated, and B and D are hypoxia treated. 
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 The results of endoglin protein levels measured by ELISA are shown in Figure 
5.2. This figure demonstrates a similar finding to what can be observed in the 
immunocytochemical staining. There was no significant difference in protein levels 
between the hypoxic and normoxic mature endothelial cell samples; nor was there a 
significant difference between either of the mature EC sample endoglin levels and those 
of the normoxic EPC protein levels. However, the hypoxic EPC samples demonstrated a 
3.2-fold upregulation of CD105 protein (p<0.01) relative to the normoxic samples of this 
cell type. 
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Figure 5.2. Endoglin protein levels from mature ECs and CD133+/CD43+ EPCs after 24 
hours of treatment with either normoxia or hypoxia. * -  p<0.01. 
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5.3.2 Assessment of Rat Oxygen-Induced Retinopathy (OIR) Tissue for Endoglin 
Levels and Association with Neovascularization 
 In westerns blots from retinal tissue lysates, the CD105 levels appear higher in all 
of the OIR sample time points, and are significantly higher at two, three and six days 
post-oxygen treatment (p<0.02). While the room air-treated samples remain low and 
constant over the times observed, the OIR samples appear to increase, throughout the 
sample times with the largest amplification between day zero and day two post treatment. 
A representative western blot and graph depicting the relative quantified CD105 values 
from four separate experiments is shown in Figure 5.3. 
Retinal tissue samples taken from animals three days post-oxygen treatment were 
flatmounted and examined for CD105 and a marker of endothelial cells (Isolectin B4). 
This immunohistochemical staining is shown in Figure 5.4. Panel A shows strong 
endoglin staining in many of the neovascular lesions and some additional strong staining 
in a bit of the vessels. However, not all of the neovascular lesions are positive for CD105 
and the lesions that are positive are not uniformly staining for endoglin. Panel B depicts 
three large vessels in the retinal mid periphery between the vascular and avascular 
interface: two veins on either side of an artery. This panel demonstrates the increased 
endoglin levels in the veins at the vascular and avascular interface at the ends of the 
veins, relative to the endoglin levels in and at the end of the artery. Panel C illustrates 
more closely associated CD105 protein with the vessels at the end of a vein. Additionally, 
this panel shows strong endoglin protein overlap in most of the neovascular lesions. 
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Figure 5.3. Western blots showing endoglin at several time points in post-oxygen treated 
retinal tissue from OIR and room air-raised control animals. Samples in every lane were 
matched for protein concentration and ultimately compared to one another after being 
normalized to relative beta-actin levels. The bottom graph shows the normalized and 
averaged results of the western protein quantities. Each band was normalized to beta-
actin and every western was independently repeated at least three times. † -  p<0.02. 
 
  
  
89 
 
 
 
 
 
Figure 5.4. Endoglin and vascular staining on retinal flatmounted tissue from animals 
three days post-oxygen treatment, 14(3). Endoglin is shown in the red, and Isolectin B4 
staining of the vasculature is green. (A) Endoglin is mostly associated with neovascular 
lesions, but not all lesions are CD105 positive. (B) Endoglin is more associated with 
veins. (C) Endoglin associated with neovascular lesions and vasculature tissue. 
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Retinal tissue samples taken from animals six days post-oxygen treatment were 
flatmounted and examined for CD105 and a marker of endothelial cells (isolectin B4). 
This immunohistochemical staining is shown in Figure 5.5. The left image panels are a 
low magnification of the entire retinal flatmount and the right panels are a higher 
magnification of the neovascular lesions at the end of a vein. The top panels show the 
relatively endothelial specific isolectin B4. These panels demonstrate the typical vascular 
and neovascular staining pattern seen at this time in the OIR model. The neovascular 
lesions are predominately at the ends of veins, just on the vascular side of the vascular to 
avascular interface of the retinal mid-periphery. The middle panel shows endoglin 
staining in red. The areas of most intense staining seem to correspond with neovascular 
lesions seen in the green, isolectin B4 panels. The bottom panels demonstrate the 
combined isolectin B4 and endoglin staining. This reveals a strong association of 
endoglin with the neovascular lesions and the incompletely formed vessels right at the 
vascular border with the avascular zone. There is also a much less intense overlap of 
endoglin staining with more mature vessels found more centrally in the retinal flatmount. 
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Figure 5.5. Endoglin and vascular staining on retinal flatmounted tissue from animals six 
days post-oxygen treatment, 14(6). 
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 The results of endoglin protein levels in OIR tissue measured by ELISA are 
shown in Figure 5.6. In this experiment, some of the animals were treated with an 
intraperitoneal injection of a CXCR4 antagonist (AMD3100) at 40mg/kg on zero and 
three days post-oxygen treatment. This antagonist has been shown to potently and 
specifically antagonize  CXCR4(95-97), prevent CXCR4/SDF-1 mediated binding and 
homing of progenitor cells(98, 99), and reduce progenitor cell mediated 
neovascularization(100). This figure demonstrates a similar finding to what can be 
observed in the western blot analysis of this tissue in Figure 5.3. There was no 
significant difference in protein levels between the room air-raised samples at either time; 
nor was there a significant difference between either of OIR sample endoglin levels at 
either time. However, the OIR samples demonstrated a 3.7-fold upregulation of CD105 
protein (p<0.01) relative to the room air-raised samples at three days post-oxygen 
treatment, and a 4.8-fold upregulation (p<0.01) at six days post-oxygen treatment. 
Additionally, there was a 46% (p<0.05) and 50% (p<0.05) reduction in CD105 protein 
levels in the samples treated with AMD3100 relative to the OIR samples at days three 
and six post-oxygen removal. 
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Figure 5.6. Endoglin protein levels in retinal tissue from OIR and room air-raised 
animals. This tissue was collected at three and six days post-oxygen exposure. * -  
p<0.02. 
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5.3.3 Assessment of EPC Homing and Recruitment in a Hypoxic Endothelial 
Monolayer Adherence Model 
The findings in Figure 5.7 demonstrate the increased adherence CD133+/CD34+  
EPCs on hypoxic endothelial monolayers, was unaffected by treatment with anti-rat IgG 
at 100µg/ml. In these samples there was a 36% reduction (p<0.05) in rolling velocity on 
the hypoxic monolayer relative to the normoxic control. Treatment with 5µg/ml of the 
CXCR4 antagonist prevented this reduction in rolling velocity to non-significant levels. 
However, treatment of the EPCs with anti-CD105 at 100µg/ml had no effect on the 
adherence of the cells. In these samples, there was a 44% reduction (p<0.05) in the 
rolling velocity on the hypoxic monolayer relative to the normoxic control. This 
difference was not significantly different from that of the anti-rat IgG control. 
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Figure 5.7. The effect of anti-CD105 treatment on mature EC and EPC homing ability. 
Rolling velocities of the cells are measured and a slower rolling velocity is indicative of 
increased adherence to the endothelial monolayer. The graph to the left is the average 
accumulated distance of the cells at each time point during the assay and the graph to the 
right shows the average rolling velocity of each cell type for the entire assay. * - p<0.05. 
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5.3.4 VEGF- and Serum-Mediated Endothelial Cell Capillary Tube Formation and 
Incorporation by EPCs  
This assay should model the effect that homing EPCs would have on endogenous 
endothelial cells that are proliferating and forming new capillary networks in angiogenic 
or neovascular tissue. The top row (A-C) of Figure 5.8 shows control anti-rat IgG at 
100µg/ml treatment conditions, and the bottom row (D-F) is a treatment of anti-CD105 at 
100µg/ml. The first column (A, D) of the figure shows how the endothelial cells and 
EPCs react in an environment that is free of serum, Here the cells clump, with addition of 
the EPCs and grow out from these clumped cell colonies. The anti-CD105 treatment 
reduces the tubes that are formed from these cell colonies. The middle column of the 
figure (B, E) is stimulated with 50ng/ml VEGF. There appears to be a slight effect of the 
anti-endoglin treatment with some reduction in tube formation in panel E. The right most 
column of the figure (C, F) is treated with the strongest tube forming stimulant, 10% 
serum. These panels show no apparent difference with anti-CD105 treatment. 
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Figure 5.8. The effect of anti-CD105 treatment on mature EC tube formation and the 
ability of EPCs to incorporate into capillaries. In these experiments the mature 
endothelial cells were prelabeled with a green fluorescent tracker and the EPC 
subpopulations were labeled with a red fluorescent tracker. 
 
  
 ug/ml 
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Figure 5.9 shows a graphically quantified representation of the panels in Figure 
5.8, however, the tube formation was quantified by the cell type: EPCs (red cells) or 
mature ECs (green cells). The data in this figure generally agrees with that from the 
figures, showing significant increases in tube formation from serum free with the addition 
of either VEGF or 10% serum, p<0.01 for both. Anti-VEGF therapy was able to produce 
a 42% reduction (p<0.05) in tube length in ECs and a 31% reduction (p<0.05) in EPCs. 
Anti-CD105 had no significant effect on EC tube formation, but did result in a 15% 
reduction in EPCs (p<0.05). Finally, the combination of anti-CD105 and anti-VEGF 
produced a 48% reduction (p<0.05) in ECs tube length, however, this reduction was not 
significantly different from anti-VEGF alone. In EPCs, the combination treatment 
resulted in a 44% reduction (p<0.02) in tube length relative to10% serum, however, it 
was not significantly different than the reduction as a result of anti-VEGF alone. 
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Figure 5.9. Graph of anti-CD105 effect on relative tube length in ECs and EPCs. The 
graph shows the quantified tube lengths of the tube formation assay demonstrated in the 
Figure 5.8 panels. All antibody treatments were performed on a 10% serum background. 
In this assay the tube lengths were normalized to the mature endothelial cell response to 
VEGF stimulation. * - p<0.05, † - p<0.02, relative to 10% serum. Statistics were 
determined by analysis of variance with a Dunnett‟s post hoc procedure. 
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5.3.5 VEGF- and Serum-Mediated Proliferation 
In Figure 5.10, the proliferation experiments for mature ECs showed a 2-fold 
response of the cells to VEGF, and a more robust 4.3-fold response of these cells to 10% 
serum. Anti-VEGF reduced proliferation by 31% (p<0.05). Anti-CD105 treatment 
reduced the proliferation in a dose dependant manner at 17% (p<0.05), 34% (p<0.05), 
and 57% (p<0.02), respectively, for each of the doses: 1-100ug/ml. The combination of 
anti-VEGF and the middle concentration of anti-CD105 (10ug/ml) significantly reduced 
proliferation by 44% (p<0.05). This combination treatment was not significant from 
either of the anti-VEGF or anti-CD105 treatments alone. 
The proliferation experiments for mature EPCs showed a 2.5-fold response of the 
cells to VEGF, and a more robust 4.2-fold response of these cells to 10% serum. Anti-
VEGF reduced proliferation by 22% (p<0.05). Anti-CD105 treatment reduced the 
proliferation in a dose dependant manner at 13% (p<0.05), 37% (p<0.05), and 59% 
(p<0.02), respectively, for each of the doses: 1-100ug/ml. The combination of anti-VEGF 
and the middle concentration of anti-CD105 (10ug/ml) significantly reduced proliferation 
by 57% (p<0.05). This combination therapy was significantly different from both anti-
VEGF and anti-CD105 at 10ug/ml (p<0.05) 
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Figure 5.10. Analysis of anti-CD105 treatment on mature EC and EPCs proliferation. All 
antibody treatments were performed on a 10% serum background. * - p<0.05, relative to 
10% serum. † - p<0.02, relative to 10% serum. ‡ - p<0.05, relative to anti-CD105 
10ug/ml. Statistics were determined by analysis of variance with a Dunnett‟s post hoc 
procedure. 
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5.3.6 In Vivo Endoglin Targeted Neovascular Inhibition in the Rat Oxygen-Induced 
Retinopathy (OIR) Model 
 Figure 5.11 shows representative retinal quadrants of OIR animals in an 
experiment looking at the effect of anti-CD105 treatment on neovascularization. The 
vasculature is stained dark brown with a lead precipitate according to the ADPase 
staining method(92). Panels A and B are non-injected and vehicles controls showing large 
neovascular lesions. Panel C illustrates an anti-VEGF treated animal with slightly 
reduced neovascularization. Panels D and E are anti-CD105 treatments at 0.1mg/ml and 
1.0mg/ml treatments, respectively. These panels show a bit of reduced neovascularization 
relative to the controls. Panel F is of a retinal quadrant from an animal treated with a 
combination of 1.0mg/ml of both anti-CD105 and anti-VEGF. This panel shows the most 
apparent reduction in neovascularization. 
Figure 5.12 is a graphical representation of the quantified neovascular lesion 
areas from the retinas depicted in Figure 5.11. Relative to vehicle, anti-VEGF treatment 
reduced neovascular area by 32% (p<0.05). Anti-CD105 treatment reduced the 
neovascular area in a dose dependant manner by 18%, 31% (p<0.05), and 47% (p<0.05), 
respectively, for each of the doses: 0.01-1.0mg/ml. The combined treatment with anti-
CD105 and anti-VEGF resulted in the greatest neovascular reduction of 62% (p<0.02), 
and this reduction in neovascular area was significantly different from the highest dose of 
anti-CD105 and the dose of anti-VEGF alone (p<0.05). 
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Figure 5.11. Comparison of representative retinal quadrants from eyes treated with anti-CD105. 
(A) No injection (B) Vehicle (C) anti-VEGF, 1.0mg/ml (D) anti-CD105, 0.1mg/ml (E) anti-
CD105, 0.1mg/ml (F) anti-CD105, 1.0mg/ml and anti-VEGF, 1.0mg/ml. 
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Figure 5.12. The effect of anti-CD105 treatment on neovascular area in rat OIR. * - p<0.05, 
relative to vehicle. † - p<0.02, relative to vehicle. ‡ - p<0.05, relative to anti-CD105 
1.0mg/ml. 
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5.4 Discussion 
 
 The experiments from this study considered as a whole suggest a role for endoglin 
in the promotion of retinal neovascularization that is associated with disease pathology in 
diabetic retinopathy and retinopathy of prematurity. Additionally, endoglin appears to be 
functioning in this angiogenic role largely through its association with endothelial 
progenitor cells involved in neovascular lesion formation. 
 In the initial in vitro experiments, endoglin was expressed at slightly higher levels 
in the EPCs than the mature ECs under normoxic conditions and then only significantly 
upregulated in the hypoxic EPCs. This was reflected and reinforced in the in vivo OIR 
model, with the significantly increased amounts of endoglin at days two, three and six 
post-oxygen exposure. Additionally, this increase in endoglin could be reduced by the 
inhibition of EPC homing to sights of neovascularization with the CXCR4 antagonist 
AMD3100. Finally, the protein expression patterns of endoglin associated closely with 
neovascular lesions and proliferative vascular areas at both 14(3) and 14(6). Three days 
post-oxygen exposure is a significant time point because this is when neovascular tufts 
are beginning to form and grow rapidly. The 14(6) time point is also significant because 
it is the peak of neovascular growth. At 14(3), there is a heterogeneous overlap of 
endoglin with the developing neovascular lesions as they begin to grow. This is possibly 
the result of a heterogeneous population of cell contributing to those lesions, such as 
EPCs and native mature ECs. Also, it is important to note the association of endoglin at 
the ends of veins at 14(3). This is particularly important because neovascular lesions 
predominantly form at these locations, at the end of veins. At the later 14(6) time, the 
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lesions are more fully developed. The association between intense endoglin staining and 
the vessels seems to be decreased and there is an increased homogeneous association of 
intense endoglin staining with large neovascular lesions. 
 In the assays examining the angiogenic capacities of EPCs, endoglin 
demonstrated significant effects on EPC proliferation. Specifically, the tube formation 
and proliferation assays were preformed with the antibody treatments on a 10% serum 
background in an effort to account for more of the growth factors responsible for 
neovascularization than VEGF alone, but also being inclusive of VEGF. In a dose 
dependent fashion, anti-CD105 treatment reduced proliferation in both ECs and EPCs, 
but having a greater effect on reducing EPC proliferation. Additionally, the combined 
therapy of anti-VEGF with anti-CD105 significantly reduced the EPC proliferation more 
than either treatment alone. In the parallel plate flow chamber cell homing assay, anti-
CD105 treatment had no significant effect on the ability of EPCs to home, however, there 
was evidence that it affected capillary tube formation and incorporation. Furthermore, in 
the tube formation assay, there wasn‟t a significant difference in a combined anti-CD105 
and anti-VEGF treatment for mature ECs, however, for EPCs there was a significant 
response reducing tube length with anti-endoglin alone and the combined treatment.  
 Finally, through the analysis of neovascular area in the OIR model, endoglin 
blockade is shown to significantly reduce the pathological lesion sizes. This reduction 
was done in a dose dependent manner, like that of the in vitro assays. Additionally, at 
equivalent concentrations anti-CD105 was more effective than anti-VEGF treatment, but 
also worked additively with anti-VEGF treatment when the two were combined to cause 
the largest reduction in neovascular lesion size.   
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Figure 5.13. Diagram demonstrating the role of endoglin in tissue-specific, EPC-mediated 
retinal neovascularization. Here the endothelial progenitor cells are originating in the bone 
marrow and entering systemic circulation. These EPCs home to and incorporate into retinal tissue 
that is hypoxic and in a proangiogenic state. In this hypoxic condition, the level of endoglin on 
the surface of EPCs is greatly increased relative to the normoxic levels and there is also a slight 
increase of endoglin on the resident mature endothelial cells in this tissue. This increased 
endoglin on the EPCs causes them to proliferate rapidly and migrate more quickly leading to a 
larger neovascular lesion. This system can be inhibited by blocking endoglin. 
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Figure 5.14. Diagram demonstrating a speculative, theoretical mechanism by which endoglin 
may be affecting EPC activity in retinal neovascularization. EPCs homing to hypoxic retinal 
tissue as well as resident mature endothelial cells in the hypoxic retinal tissue are activated to a 
more proliferative state through either the ALK1 or ALK5 pathways. (This diagram is a 
reproduction and originally published in Fonsatti et al. Cardiovasc Res. 2010 Apr 1;86(1):12-9. – 
(101). 
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All of these experiments suggest a critical role for endoglin in the EPC-mediated 
retinal neovascularization that is seen in these OIR animals. Figure 5.13 demonstrates the 
tissue specific mechanism for endoglin, while Figure 5.14 shows a more detailed 
biochemical, signaling mechanism that utilizes endoglin‟s interaction with TGFβ/ALK1 
and TGFβ/ALK5 signaling. While there aren‟t experiments in this chapter directly 
targeting the signaling mechanism of endoglin‟s effects on EPCs, there are a number of 
published studies that indicate what this mechanism might be. Tian et al. have 
demonstrated that endoglin can be upregulated by hypoxia in mature cardiovascular 
endothelial cells(102). Additionally, endoglin, through activation of TGFβ/ALK1, can 
phosphorylate SMAD1/5/8 to promote endothelial proliferation and migration or, through 
inhibition of TGFβ/ALK5 and SMAD2/3 phosphorylation can prevent endothelial cell 
quiescence(25, 101, 102). Yet another study pointing to the importance of this pathway 
demonstrated that over expression of ALK1 was able to promote the remodeling of 
retinal blood vessels(103). The experiments conducted in this chapter have shown EPCs 
to be more reactive to endoglin upregulation in hypoxia and highly active in the 
formation of neovascular lesions in OIR. It is likely that the same CD105/ALK/SMAD 
pathways that have been shown to control mature endoglin proliferation also play a role 
in EPC proliferation and migration signaling pathways. 
The results from this study are encouraging as a potentially new treatment 
pathway for ocular neovascularization that is, at least, partially independent of VEGF and 
targets endothelial progenitor cell. It is additionally promising that the endoglin and 
VEGF targeted therapies seem to work additively, which potentially would make them 
more effective when used to treat individuals with little or no effect from either therapy 
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strategy alone. Also, since they work additively, smaller doses of each could be given in 
combination. This reduced dosing may decrease any side effects that are associated with 
the treatments. Ultimately, more studies will be necessary, and endoglin seems like an 
ideal candidate for future clinical trials for ocular neovascularization. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE WORK 
 
 This dissertation is composed of four chapters that define a framework for 
studying EPCs in the context of ocular neovascularization. Using the methods developed 
in this work can help to determine the biological role of an EPC subpopulation, EPC 
associated protein, or EPC directed therapies either through their inhibition or utility as a 
drug delivery device. With this outline as an example, multiple EPC subpopulations can 
be compared, and their surface antigens and angiogenic signaling can be effectively 
examined in the context of ocular angiogenesis. Chapter II was concerned with the goal 
of developing sufficient EPC labeling and tracking methods so that a population of cells 
could be marked in an EPC specific manner (ie. the scavenger receptors that pick up the 
acLDL, one of the tools used regularly to identify EPCs). One secondary condition of this 
labeling was that it be sufficiently bright to see relatively small quantities of the 
fluorescent reagent in cells through many cellular divisions and this fluorescence needed 
to be photostable over long observation periods. Another condition was the necessity to 
label several subpopulations with an individual color. All of these conditions were met 
using acLDL conjugated quantum dots. This labeling system allowed us to sufficiently 
track EPCs in a model of laser-induced choroidal neovascularization (LCNV). This met 
the goals of specific aim 1 of this work. Future studies should concentrate on tracking 
multiple different cell types in vivo simultaneously and in both LCNV and oxygen-
induced retinopathy. 
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 Chapters III and IV were concerned with the goal of developing high throughput, 
in vitro methods to analyze the angiogenic capacity of EPCs using quantum dot coded 
subpopulations. This was first approached with the development of the parallel plate flow 
chamber (PPFC) system for analyzing EPC homing capabilities in chapter III. The work 
from chapter II was built on here through the use of the quantum dot labeling of the 
EPCs. This analysis was made possible through the adherence of the cells to coated 
surfaces and treated endothelial monolayers. The coated surfaces allow specific proteins 
like SDF-1 and extracellular matrix components like hyaluronic acid to be studied in 
terms of their influence on EPC homing. The endothelial monolayers treated with 
hypoxia, normoxia, or a mechanical injury allow the PPFC to act as a model of the inner 
luminal wall of a blood vessel. In this way the EPCs can be studied in terms of how they 
react to vessels in a variety of injury scenarios. Future studies should try to add insults to 
the endothelial monolayers, like inflamitory stimuli (ie. LPS, or interleukins) or diabetic 
modeling by pretreating the monolayers in high glucose (~25mM glucose) conditions 
before examining the EPC adherence. 
 Chapter IV built again on the work of chapters II and III by utilizing those 
methods in a more complete analysis of EPC angiogenic capacity. Here the homing 
ability of the cells was analyzed with the PPFC system. The tube formation and 
proliferation capabilities of the cells were analyzed using a unique assay that incorporated 
the quantum dot labeling method developed in chapter II to follow and distinguish EPC 
subpopulations and mature ECs. Additionally, proliferation was studied using a BrdU 
assay. Together this analytical system explored the homing, tube formation and 
incorporation, and proliferative abilities of the EPCs. Ultimately we discovered that 
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CD133+/CD34+ cells had a higher angiogenic capacity in retinal angiogenesis compared 
to Tie2+/CD133+ cells or a heterogeneous population of EPCs. This work concluded the 
goals set in specific aim 2 of this work, which was to develop this analytical system. 
Future studies into this work should concentrate on analyzing more subpopulations of 
cells for their specific differences and characteristic activities in retinal 
neovascularization. 
 Chapter V built on the progress of the previous three chapters to determine the 
biological role of an EPC associated protein demonstrating the utility of this system of 
analysis. Endoglin was studied in the context of retinal neovascularization and 
determined to have an angiogenic role in neovascularization, largely through its 
proliferative effects on EPCs.  This study fulfilled the goals of specific aim three, 
identifying, validating and examining the EPC associated protein and finding it to be a 
valid therapeutic target for the inhibition of neovascularization using an antibody to block 
its cellular function. Future studies should use this system to analyze more EPC 
associated proteins, more EPC subpopulations in the context of these assays, and track 
multiple EPC subpopulations in vivo in order to validate an EPC associated protein target. 
Additionally, the signaling pathways of endoglin on both EPCs and retinal endothelial 
cells should be further explored. There is promising evidence in the literature that 
endoglin is functioning through TGFβ/ALK1/SMAD1/5/8 to promote endothelial 
proliferation and through inhibition of TGFβ/ALK5/SMAD2/3 to prevent endothelial 
quiescence. There are a number of ALK1 and ALK5 inhibitors available that would make 
studying these pathways more feasible(104, 105), and many of the natural agonists like 
TGFβ and the BMPs should be explored as well.  
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 There are a number of other studies that could be done involving endoglin and 
haplotype patient studies or animal endoglin deletion studies. Endoglin has a human 
correlative disease related to missense mutations in CD105, ALK1 or SMAD4(106-108). 
These mutations lead to hereditary hemorrhagic telangiectasia (HHT), also known as 
Osler-Weber-Rendu disease. This is an autosomal dominant genetic disorder 
characterized by arteriovenous malformations, hemorrhages, fistulas, and ulcers. These 
malformations can range from irritable ulcers in the mouth, skin and sclera to life-
threatening hemorrhages in the lungs, liver or brain. While there are not many studies 
looking directly at the effects of HHT on retinal vascular development or formation, there 
are a small number of case studies that suggest an interesting role. Studies have shown 
that patients with HHT can present with retinopathy similar to that of diabetic 
retinopathy(109) and retinal abnormalities consisting mainly of choriocapillaris 
atrophy(110). These would suggest that endoglin pathway loss leads to a lack of vascular 
growth in the retina. Additionally, HHT patients demonstrate high plasma VEGF levels 
and correspondingly high focal areas of high tissue VEGF levels(111). This may be a 
constitutive tissue response to the absence of endoglin in an attempt to achieve vascular 
homeostasis. Without the proliferative and developmental cues from endoglin, an 
underdevelopment of the vasculature occurs resulting in an over production of VEGF 
from the surrounding, undernourished tissue. This would also suggest that the VEGF and 
endoglin pathways are separate. Interestingly, the anti-VEGF therapy, Avastin, has been 
successfully used in HHT patients to treat liver hemorrhaging preventing the need for 
transplants(112) and epistaxis(113). These findings also suggest separate signaling 
pathways for VEGF and endoglin. With these findings in mind, it may be beneficial to 
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perform a retrospective patient study comparing HHT patients and controls while 
focusing on the incidences of vascular diseases in the eye such as retinopathy of 
prematurity, diabetic retinopathy and age-related macular degeneration. Animal models 
could be useful to this end as well. While, an endoglin knockout mouse has embryonic 
lethality, an endoglin conditional knockout is available and demonstrates vascular 
abnormalities including delayed vascular remodeling and reduced numbers of new blood 
vessels(114, 115). Additionally, the heterogenous knockout mouse, which has no 
embryonic lethality would be an ideal model animal for HHT and studying both the 
vascular disorders of the eye in these patients and the influence of endoglin pathway 
signaling in these disorders. These animals could be invaluable through their use in the 
oxygen-induced retinopathy model and the laser-induced choroidal neovascularization 
model. The combination of these biological tools, the easy access of the retinal 
vasculature, and the continued research developments pointing to the importance of 
endoglin in vascular biology indicate that it is a prime moment to explore this molecule. 
With its many developing roles in vascular growth and development, endoglin should be 
carefully studied particularly in terms of its potential therapeutic targeting in vascular 
diseases of the eye.  
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